1
|
Patel KR, Wang B, Abdelhamid Ahmed AH, Okose OC, Ma H, Behr IJ, Cheung AY, Saito Y, Kamani D, Silver Karcioglu A, Liddy W, Takami H, Cunnane M, Randolph GW. Surgical and Biochemical Outcomes in Nerve Monitored Reoperation Surgery for Recurrent Papillary Thyroid Carcinoma. Otolaryngol Head Neck Surg 2023; 169:1234-1240. [PMID: 37245079 DOI: 10.1002/ohn.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 04/20/2023] [Accepted: 05/01/2023] [Indexed: 05/29/2023]
Abstract
OBJECTIVE To study the surgical and biochemical outcomes in nerve-monitored reoperation or revision surgery for recurrent thyroid cancers. STUDY DESIGN A single-center retrospective study. SETTING Tertiary center. METHODS We identified patients with recurrent papillary thyroid carcinoma (PTC) who underwent reoperation/revision surgery. Study outcomes were surgical complications frequency, recurrence, distant metastasis, and biological complete response (BCR) by comparing preoperative and postoperative thyroglobulin (Tg) levels. RESULTS Out of 227 patients, 33.9% presented for ≥2 reoperation surgeries. Nineteen (8.4%) had permanent preoperative hypoparathyroidism while 22 patients (9.7%) had preoperative vocal cord paralysis (VCP). Following reoperation surgery, there were 12 cases (5.3%) of permanent hypocalcemia and no cases of unexpected postoperative VCP. BCR was achieved in 31 patients (35.2%) with complete Tg data. Mean preoperative Tg was 47.7 ng/mL and was 19.7 ng/mL postoperatively (p = .003). The cervical nodal recurrence rate after final surgery was 7.0% (n = 16). CONCLUSION Reoperation surgery for recurrent PTC may help achieve biochemical remission regardless of age or the number of prior surgeries.
Collapse
Affiliation(s)
- Krupa R Patel
- Department of Otolaryngology-Head and Neck Surgery, Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - Bo Wang
- Department of Otolaryngology-Head and Neck Surgery, Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
- Department of Thyroid Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China
| | - Amr H Abdelhamid Ahmed
- Department of Otolaryngology-Head and Neck Surgery, Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - Okenwa C Okose
- Department of Otolaryngology-Head and Neck Surgery, Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - Honghzhi Ma
- Department of Otolaryngology-Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China
- Key Laboratory of Otorhinolaryngology-Head and Neck Surgery, Ministry of Education, Beijing Institute of Otorhinolaryngology, Beijing, China
| | - Ian J Behr
- Department of Otolaryngology-Head and Neck Surgery, Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - Anthony Y Cheung
- Department of Otolaryngology-Head and Neck Surgery, Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - Yoshiyuki Saito
- Department of Otolaryngology-Head and Neck Surgery, Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
- Department of Surgery, Keio University School of Medicine, Tokyo, Japan
| | - Dipti Kamani
- Department of Otolaryngology-Head and Neck Surgery, Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - Amanda Silver Karcioglu
- Department of Otolaryngology-Head and Neck Surgery, Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
- Division of Otolaryngology-Head and Neck Surgery, NorthShore University HealthSystem, Evanston, Illinois, USA
| | - Whitney Liddy
- Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | | | - MaryBeth Cunnane
- Department of Radiology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA
| | - Gregory W Randolph
- Department of Otolaryngology-Head and Neck Surgery, Division of Thyroid and Parathyroid Endocrine Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
- Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
2
|
Saito Y, Watanabe N, Suzuki N, Saito N, Narimatsu H, Takami H, Kameyama K, Yoshioka K, Masaki C, Akaishi J, Hames KY, Matsumoto M, Fukushita M, Yoshihara A, Okamura R, Tomoda C, Suzuki A, Matsuzu K, Kitagawa W, Nagahama M, Noh JY, Sugino K, Ito K. Role of Surgery in Patients with Stage IE Primary Thyroid MALT Lymphoma Staged by a Modified Classification System: The Tokyo Classification. Cancers (Basel) 2023; 15:cancers15051451. [PMID: 36900242 PMCID: PMC10000773 DOI: 10.3390/cancers15051451] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Revised: 02/17/2023] [Accepted: 02/21/2023] [Indexed: 03/03/2023] Open
Abstract
PURPOSES To establish the appropriate staging system and assess the role of curative thyroidectomy alone (Surgery) vs. involved-site radiation therapy after open biopsy (OB-ISRT) in stage IE mucosa-associated lymphoid tissue (MALT) lymphoma. METHODS We examined the Tokyo Classification as a modified classification. This retrospective cohort study included 256 patients with thyroid MALT lymphoma; 137 underwent standard therapy (i.e., OB-ISRT) and were enrolled for the Tokyo classification. Sixty stage IE patients with the same diagnosis were examined to compare Surgery with OB-ISRT. RESULTS Overall survival (p = 0.0092) and relapse-free survival (0.00113) were significantly better in stage IE vs. stage IIE under the Tokyo classification. No OB-ISRT and Surgery patients died, but three OB-ISRT patients relapsed. The incidence of permanent complications was 28% in OB-ISRT (mainly dry mouth) and 0% in Surgery (p = 0.027). The number of painkiller prescription days was significantly greater in OB-ISRT (p < 0.001). During follow-up, the rate of the new appearance/change of the low-density area in the thyroid gland was significantly higher in OB-ISRT (p = 0.031). CONCLUSIONS The Tokyo classification allows an appropriate discrimination between stages IE and IIE MALT lymphoma. Surgery can provide a good prognosis in stage IE cases; it also avoids complications, shortens painful periods during treatment, and simplifies ultrasound follow-up.
Collapse
Affiliation(s)
- Yoshiyuki Saito
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
- Correspondence: ; Tel.: +81-3-3402-7411
| | - Natsuko Watanabe
- Department of Internal Medicine, Ito Hospital, Tokyo 150-8308, Japan
| | - Nami Suzuki
- Department of Internal Medicine, Ito Hospital, Tokyo 150-8308, Japan
| | - Naoko Saito
- Department of Radiology, Juntendo University, Tokyo 113-8431, Japan
| | - Hiroto Narimatsu
- Cancer Prevention and Control Division, Kanagawa Cancer Center, Yokohama 241-8515, Japan
- Graduate School of Health Innovation, Kanagawa University of Human Services, Kawasaki 238-8522, Japan
| | - Hiroshi Takami
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | - Kaori Kameyama
- Department of Pathology, Showa University Northern Yokohama Hospital, Yokohama 224-8503, Japan
| | - Kana Yoshioka
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | - Chie Masaki
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | - Junko Akaishi
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | | | - Masako Matsumoto
- Department of Internal Medicine, Ito Hospital, Tokyo 150-8308, Japan
| | - Miho Fukushita
- Department of Internal Medicine, Ito Hospital, Tokyo 150-8308, Japan
| | - Ai Yoshihara
- Department of Internal Medicine, Ito Hospital, Tokyo 150-8308, Japan
| | | | - Chisato Tomoda
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | - Akifumi Suzuki
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | | | | | | | | | | | - Koichi Ito
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| |
Collapse
|
3
|
Iwasaki H, Takami H, Yasuhiro I, Takahiro O, Iwao S, Kiminori S, Shunji T, Hiroshi T, Hidemitsu T, Hisato H, Ayako M, Hiroyuki Y, Yasuo O, Takeru S, Tuneo I, Makoto T. PS4-2 Analysis of the COLLECT Study - Efficacy and safety of lenvatinib in differentiated thyroid cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.05.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
4
|
Saito Y, Ikeda Y, Takami H, Nakao A, Ho K, Tokuda T, Miyata R, Tomita M, Sato M, Ando N. Combined thoracoscopic and axillary subcutaneous endoscopic thyroidectomy: a novel approach for cervicomediastinal goiters. Langenbecks Arch Surg 2022; 407:2169-2175. [PMID: 35689707 DOI: 10.1007/s00423-022-02579-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Accepted: 06/01/2022] [Indexed: 10/18/2022]
Abstract
PURPOSE After our group described the first remote-access thyroidectomy series in 2000, the procedure has been further developed. Although a thoracoscopic approach with a conventional open cervical incision for thyroid goiters with mediastinal extension has been performed at many institutions, remote-access thyroidectomy for cervicomediastinal goiters has not been established. We have performed combined thoracoscopic and axillary subcutaneous endoscopic thyroidectomies (axillo-thoracic endoscopic thyroidectomies). Here, we describe a novel technique for performing a remote-access thyroidectomy for a cervicomediastinal goiter (CMG). PATIENTS AND METHODS The patients with CMGs who agreed to an axillo-thoracic endoscopic thyroidectomy at one of two hospitals in Japan underwent a remote-access thyroidectomy. RESULTS We performed the axillo-thoracic endoscopic right or left hemithyroidectomy successfully, but most of the patients did not require the thoracoscopic procedure. None of the patients had complications, and none was converted to an open thyroidectomy. CONCLUSIONS Most thyroid goiters with substernal extension can be removed by the axillary approach, but some cases require a thoracoscopic approach. The novel approach described herein (axillo-thoracic endoscopic thyroidectomy) enables the safe excision of a CMG with high patient satisfaction for selected patients.
Collapse
Affiliation(s)
- Yoshiyuki Saito
- Department of Surgery, International Goodwill Hospital, 1-28-1 Nishigaoka, Izumi-ku, Yokohama, Kanagawa, 245-0006, Japan. .,Department of Surgery, Keio University School of Medicine, Tokyo, Japan. .,Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA. .,Department of Surgery Gastroenterology Center, International University of Health and Welfare, Mita Hospital, Tokyo, Japan.
| | - Yoshifumi Ikeda
- Department of Surgery Gastroenterology Center, International University of Health and Welfare, Mita Hospital, Tokyo, Japan.,Department of Surgery, International University of Health and Welfare, Atami Hospital, Atami, Shizuoka, Japan
| | | | - Atsushi Nakao
- Department of Surgery, International Goodwill Hospital, 1-28-1 Nishigaoka, Izumi-ku, Yokohama, Kanagawa, 245-0006, Japan.,Department of Surgery, Keio University School of Medicine, Tokyo, Japan
| | - Keiso Ho
- Department of Surgery, International Goodwill Hospital, 1-28-1 Nishigaoka, Izumi-ku, Yokohama, Kanagawa, 245-0006, Japan
| | - Toshiki Tokuda
- Department of Surgery, International Goodwill Hospital, 1-28-1 Nishigaoka, Izumi-ku, Yokohama, Kanagawa, 245-0006, Japan
| | - Ryohei Miyata
- Department of Surgery, International Goodwill Hospital, 1-28-1 Nishigaoka, Izumi-ku, Yokohama, Kanagawa, 245-0006, Japan
| | - Masato Tomita
- Department of Surgery, International Goodwill Hospital, 1-28-1 Nishigaoka, Izumi-ku, Yokohama, Kanagawa, 245-0006, Japan
| | - Michio Sato
- Department of Surgery, International Goodwill Hospital, 1-28-1 Nishigaoka, Izumi-ku, Yokohama, Kanagawa, 245-0006, Japan
| | - Nobutoshi Ando
- Department of Surgery, International Goodwill Hospital, 1-28-1 Nishigaoka, Izumi-ku, Yokohama, Kanagawa, 245-0006, Japan
| |
Collapse
|
5
|
Saito Y, Ikeda Y, Takami H, Abdelhamid Ahmed AH, Nakao A, Katoh H, Ho K, Tomita M, Sato M, Tolley NS, Randolph GW. A scoping review of approaches used for remote-access parathyroidectomy: A contemporary review of techniques, tools, pros and cons. Head Neck 2022; 44:1976-1990. [PMID: 35467046 DOI: 10.1002/hed.27068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Revised: 03/24/2022] [Accepted: 04/12/2022] [Indexed: 11/09/2022] Open
Abstract
After our coauthors described the first remote-access parathyroidectomy (RAP) series in 2000, several other approaches were developed. No systematic review has been performed to classify and evaluate RAP techniques. We performed a literature search using PubMed and Cochrane Library (CENTRAL). A total of 71 studies met our inclusion/exclusion criteria. RAP can be categorized into five approaches: (1) endoscopic and robotic axillary, (2) anterior chest, (3) transoral, (4) retroauricular, and (5) a combination of these approaches. The limited data in the literature suggest that the cure rates and safety of RAP are in no way inferior to those of open parathyroidectomy. Each approach has its advantages and disadvantages, and the recommendations for the selection of each approach are listed. The selection of approach methods might depend on the surgeon's experience and familiarity and the patient's preference and disease status.
Collapse
Affiliation(s)
- Yoshiyuki Saito
- Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA.,Department of Surgery, International Goodwill Hospital, Yokohama, Japan.,Department of Surgery, Keio University School of Medicine, Tokyo, Japan
| | - Yoshifumi Ikeda
- Department of Surgery, International University of Health and Welfare, Atami Hospital, Atami, Japan
| | | | - Amr H Abdelhamid Ahmed
- Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - Atsushi Nakao
- Department of Surgery Gastroenterology Center, International University of Health and Welfare, Mita Hospital, Tokyo, Japan
| | - Hiroshi Katoh
- Department of Surgery, Kitasato University School of Medicine, Sagamihara, Japan
| | - Keiso Ho
- Department of Surgery, International Goodwill Hospital, Yokohama, Japan
| | - Masato Tomita
- Department of Surgery, International Goodwill Hospital, Yokohama, Japan
| | - Michio Sato
- Department of Surgery, International Goodwill Hospital, Yokohama, Japan
| | | | - Gregory W Randolph
- Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology - Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA.,Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
6
|
Liddy W, Wu CW, Dionigi G, Donatini G, Giles Senyurek Y, Kamani D, Iwata A, Wang B, Okose O, Cheung A, Saito Y, Casella C, Aygun N, Uludag M, Brauckhoff K, Carnaille B, Tunca F, Barczyński M, Kim HY, Favero E, Innaro N, Vamvakidis K, Serpell J, Romanchishen AF, Takami H, Chiang FY, Schneider R, Dralle H, Shin JJ, Abdelhamid Ahmed AH, Randolph GW. Varied Recurrent Laryngeal Nerve Course Is Associated with Increased Risk of Nerve Dysfunction During Thyroidectomy: Results of the Surgical Anatomy of the Recurrent Laryngeal Nerve in Thyroid Surgery Study, an International Multicenter Prospective Anatomic and Electrophysiologic Study of 1000 Monitored Nerves at Risk from the International Neural Monitoring Study Group. Thyroid 2021; 31:1730-1740. [PMID: 34541890 DOI: 10.1089/thy.2021.0155] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Background: The recurrent laryngeal nerve (RLN) can be injured during thyroid surgery, which can negatively affect a patient's quality of life. The impact of intraoperative anatomic variations of the RLN on nerve injury remains unclear. Objectives of this study were to (1) better understand the detailed surgical anatomic variability of the RLN with a worldwide perspective; (2) establish potential correlates between intraoperative RLN anatomy and electrophysiologic responses; and (3) use the information to minimize complications and assure accurate and safe intraoperative neuromonitoring (IONM). Methods: A large international registry database study with prospectively collected data was conducted through the International Neural Monitoring Study Group (INMSG) evaluating 1000 RLNs at risk during thyroid surgery using a specially designed online data repository. Monitored thyroid surgeries following standardized IONM guidelines were included. Cases with bulky lymphadenopathy, IONM failure, and failed RLN visualization were excluded. Systematic evaluation of the surgical anatomy of the RLN was performed using the International RLN Anatomic Classification System. In cases of loss of signal (LOS), the mechanism of neural injury was identified, and functional evaluation of the vocal cord was performed. Results: A total of 1000 nerves at risk (NARs) were evaluated from 574 patients undergoing thyroid surgery at 17 centers from 12 countries and 5 continents. A higher than expected percentage of nerves followed an abnormal intraoperative trajectory (23%). LOS was identified in 3.5% of NARs, with 34% of LOS nerves following an abnormal intraoperative trajectory. LOS was more likely in cases of abnormal nerve trajectory, fixed splayed or entrapped nerves (including at the ligament of Berry), extensive neural dissection, cases of cancer invasion, or when lateral lymph node dissection was needed. Traction injury was found to be the most common form of RLN injury and to be less recoverable than previous reports. Conclusions: Multicenter international studies enrolling diverse patient populations can help reshape our understanding of surgical anatomy during thyroid surgery. There can be significant variability in the anatomic and intraoperative characteristics of the RLN, which can impact the risk of neural injury.
Collapse
Affiliation(s)
- Whitney Liddy
- Department of Otolaryngology-Head and Neck Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
| | - Che-Wei Wu
- Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Gianlorenzo Dionigi
- Division for Endocrine and Minimally Invasive Surgery, Department of Human Pathology in Adulthood and Childhood "Gaetano Barresi," University Hospital G. Martino, University of Messina, Messina, Italy
| | - Gianluca Donatini
- Department of Visceral and Endocrine Surgery, CHU Poitiers-University of Poitiers, Poitiers, France
| | - Yasemin Giles Senyurek
- Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Dipti Kamani
- Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - Ayaka Iwata
- Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
- Department of Otolaryngology-Head and Neck Surgery, Kaiser Permanente Santa Clara Medical Center, Santa Clara, California, USA
| | - Bo Wang
- Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
- Department of Thyroid and Parathyroid Surgery, Fujian Medical University Union Hospital, Fujian, China
| | - Okenwa Okose
- Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - Anthony Cheung
- Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - Yoshiyuki Saito
- Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
- Department of Surgery, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Tokyo, Japan
| | - Claudio Casella
- Department of Molecular and Translational Medicine, School of Medicine, University of Brescia Surgical Clinic, Spedali Civili Brescia, Brescia, Italy
| | - Nurcihan Aygun
- Department of General Surgery, University of Health Sciences Turkey, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey
| | - Mehmet Uludag
- Department of General Surgery, University of Health Sciences Turkey, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey
| | - Katrin Brauckhoff
- Department of Breast and Endocrine Surgery, Haukeland University Hospital, Bergen, Norway
- Department of Clinical Science, University of Bergen, Bergen, Norway
| | - Bruno Carnaille
- Department of General and Endocrine Surgery, Lille University Hospital, Lille University, Lille, France
| | - Fatih Tunca
- Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Marcin Barczyński
- Department of Endocrine Surgery, Third Chair of General Surgery, Jagiellonian University, Medical College, Kraków, Poland
| | - Hoon Yub Kim
- Department of Surgery, Korea University Thyroid Center, Korea University College of Medicine, Seongbuk-gu, Seoul, Korea
- Division of Endocrine and Oncologic Surgery, Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA
| | - Emerson Favero
- Department of Head and Neck Surgery, School of Medicine, University of Mogi das Cruzes, São Paulo, Brazil
| | - Nadia Innaro
- Unit of Endocrine Surgery, AOU Mater Domini, Catanzaro, Italy
| | - Kyriakos Vamvakidis
- Department of Endocrine Surgery, "Henry Dunant" Hospital Center, Athens, Greece
| | - Jonathan Serpell
- Med, Breast, Endocrine and General Surgery Unit, Alfred Health, Monash University, Melbourne, Victoria, Australia
| | | | - Hiroshi Takami
- Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan
| | - Feng-Yu Chiang
- Department of Otolaryngology, E-Da Hospital, School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan
| | - Rick Schneider
- Department of Visceral, Vascular and Endocrine Surgery, University Hospital Halle, Martin-Luther University, Halle (Saale), Germany
| | - Henning Dralle
- Division of Endocrine Surgery, Department of General, Visceral and Transplantation Surgery, University of Duisburg Essen, Essen, Germany
| | - Jennifer J Shin
- Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts, USA
- Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Amr H Abdelhamid Ahmed
- Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - Gregory W Randolph
- Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
- Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
7
|
Saito Y, Takami H, Abdelhamid Ahmed AH, Nakao A, Ho K, Tokuda T, Miyata R, Randolph GW, Ando N. Association of symptomatic gallstones and primary hyperparathyroidism: a propensity score-matched analysis. Br J Surg 2021; 108:e336-e337. [PMID: 34370814 PMCID: PMC10364881 DOI: 10.1093/bjs/znab249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Revised: 06/02/2021] [Accepted: 06/10/2021] [Indexed: 11/12/2022]
Abstract
If the prevalence of primary hyperparathyroidism (PHPT) in patients with symptomatic gallstones is higher than that in the general population, PHPT screening could reveal important clinical implications. We observed that the prevalence of PHPT in these patients was higher compared to that of healthy matched controls.
Collapse
Affiliation(s)
- Y Saito
- Department of Surgery, International Goodwill Hospital, Yokohama, Kanagawa, Japan.,Department of Surgery, Keio University School of Medicine, Tokyo, Japan.,Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA
| | - H Takami
- Department of Surgery, Ito Hospital, Tokyo, Japan
| | - A H Abdelhamid Ahmed
- Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA
| | - A Nakao
- Department of Surgery, International Goodwill Hospital, Yokohama, Kanagawa, Japan
| | - K Ho
- Department of Surgery, International Goodwill Hospital, Yokohama, Kanagawa, Japan
| | - T Tokuda
- Department of Surgery, International Goodwill Hospital, Yokohama, Kanagawa, Japan
| | - R Miyata
- Department of Surgery, International Goodwill Hospital, Yokohama, Kanagawa, Japan
| | - G W Randolph
- Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA
| | - N Ando
- Department of Surgery, International Goodwill Hospital, Yokohama, Kanagawa, Japan
| |
Collapse
|
8
|
Tahara M, Takami H, Ito Y, Okamoto T, Sugitani I, Sugino K, Takahashi S, Takeyama H, Tsutsui H, Hara H, Mitsuma A, Yamashita H, Ohashi Y, Imai T. Planned drug holiday in a cohort study exploring the effect of lenvatinib on differentiated thyroid cancer. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.6070] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6070 Background: Lenvatinib is now available for unresectable radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). However, toxicities are considerable and require frequent dose interruption and modification. Recently, planned drug holidays, which are dose interruptions in accordance with the timing of severe or intolerable adverse events, have been proposed to avoid severe adverse events due to lenvatinib (Tahara M.ESMO Open 2018). Our retrospective study demonstrated that progression-free survival (PFS) and overall survival (OS) were significantly longer in patients who used planned drug holidays than those who did not (Matsuyama C et.al, 2020 Annual Meeting of the Japan Association of Endocrine Surgeons). Methods: In this prospective observational study, patients with curatively unresectable and progressive RAI-refractory DTC were treated with lenvatinib in a real-world clinical setting. Lenvatinib was administered orally at a dose of 24 mg daily. Dose modification for toxicities were permitted. Primary endpoint was OS, and secondary endpoints were time to treatment failure (TTF), time to failure of strategy (TFS), PFS with clinical progressive disease, response rate, quality of life, safety, and patient reports. This study was registered with UMIN Clinical Trials Registry (UMIN000022243). Results: 262 patients were accrued. Of 255 evaluable, 153 were female; median age was 70 (range 27.0-88.0); histology was papillary thyroid carcinoma/follicular thyroid carcinoma/poorly DTC in 204/45/4; previous therapy was surgery/RAI/molecular targeted drug in 246/164/14; reason for initiation of lenvatinib was disease progression/unsuitable for RAI in 241/4. 1-year OS was 85.6% (95%CI: 80.6-89.4%); 1-year TTF rate was 74.9% (95%CI: 69.1-79.8%); 1-year TFS rate was 80.8% (95%CI: 75.4-85.2%); and 1-year PFS rate was 84.4% (95%CI: 79.3-88.4%). Overall response by RECIST was 3 (1.2%) in CR and 151 (61.9%) in PR. Most common grade 3 or 4 toxicities were hypertension (61.4%), hand foot syndrome (10.2%), fatigue (9.1%), anorexia (8.3%) and diarrhea (4.7%). Grade 5 toxicities occurred in 4 patients (fistula, hypoxia, respiratory failure, trachea stenosis). Of 253 patients evaluable for efficacy, 73 used planned drug holidays. TTF, TFS and PFS were significantly longer in patients who used planned drug holiday than those who did not (Table). Conclusions: Planned drug holiday for lenvatinib demonstrated significantly better clinical outcomes, including TTF, TFS and PFS, than daily oral administration. These data further support use of a planned drug holiday in RAI-refractory DTC patients receiving lenvatinib. Clinical trial information: 000022243. [Table: see text]
Collapse
Affiliation(s)
- Makoto Tahara
- Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | | | | | - Takahiro Okamoto
- Department of Breast and Endocrine Surgery, Tokyo Women's Medical University, Tokyo, Japan
| | - Iwao Sugitani
- Nippon Medical School Graduate School of Medicine, Tokyo, Japan
| | | | - Shunji Takahashi
- Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
| | | | | | - Hisato Hara
- Department of Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | | | | | - Yasuo Ohashi
- Department of Integrated Science and Engineering, Chuo University, Tokyo, Japan
| | - Tsuneo Imai
- National Hospital Organization, Higashinagoya National Hospital, Nagoya, Japan
| |
Collapse
|
9
|
Nakao A, Saito Y, Ikeda Y, Takami H, Hoshino G, Miyata R, Tomita M, Sato M, Ishikura N, Mitsuya T, Ando N. Total endoscopic thyroidectomy after open neck biopsy of the follicular lymphoma of the thyroid gland. Asian J Endosc Surg 2021; 14:275-278. [PMID: 32789975 DOI: 10.1111/ases.12847] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2020] [Revised: 07/02/2020] [Accepted: 07/09/2020] [Indexed: 01/08/2023]
Abstract
Remote-access total endoscopic thyroidectomy (TET) is a recently established approach that can avoid producing scars in the neck. There are no clear surgical indications for TET for benign nodules or for malignant tumors at present. We report a successful TET in a 50-year-old Japanese woman with follicular lymphoma of the thyroid gland after an open neck biopsy. She had been referred to us with a neck tumor noted 2 months earlier. Because of adhesion, we performed a combined resection of the thyroid and partial right sternohyoid muscle. To the best of our knowledge, there is no other report of a TET performed after open neck surgery. Our patient's case demonstrates that (a) the cosmetic outcome of TET is clearly superior to that of conventional open neck surgery, and (b) a TET can be suitable even for reoperation if carefully selected.
Collapse
Affiliation(s)
- Atsushi Nakao
- Department of Surgery, International Goodwill Hospital, Yokohama, Japan
| | - Yoshiyuki Saito
- Department of Surgery, International Goodwill Hospital, Yokohama, Japan
| | - Yoshifumi Ikeda
- Department of Surgery, International University of Health and Welfare, Atami Hospital, Atami, Japan
| | | | - Go Hoshino
- Department of Surgery, International Goodwill Hospital, Yokohama, Japan
| | - Ryohei Miyata
- Department of Surgery, International Goodwill Hospital, Yokohama, Japan
| | - Masato Tomita
- Department of Surgery, International Goodwill Hospital, Yokohama, Japan
| | - Michio Sato
- Department of Surgery, International Goodwill Hospital, Yokohama, Japan
| | - Naoyo Ishikura
- Department of Pathology, International Goodwill Hospital, Yokohama, Japan
| | - Toshiyuki Mitsuya
- Department of Pathology, International Goodwill Hospital, Yokohama, Japan
| | - Nobutoshi Ando
- Department of Surgery, International Goodwill Hospital, Yokohama, Japan
| |
Collapse
|
10
|
Saito Y, Ikeda Y, Katoh H, Nakao A, Takami H. Is total endoscopic parathyroidectomy an acceptable treatment for patients with primary hyperparathyroidism due to a presumed solitary adenoma?-comparison of minimally invasive total endoscopic parathyroidectomy and open minimally invasive parathyroidectomy. Gland Surg 2021; 10:83-89. [PMID: 33633965 DOI: 10.21037/gs-20-526] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Background Remote-access thyroidectomy and its cosmetic merit have been widely accepted, but remote-access parathyroidectomy has not become common. There are few reports about the risks and effectiveness of a remote-access endoscopic parathyroidectomy. Herein, we evaluated the risks and benefits of total endoscopic parathyroidectomy (TEP) for patients with primary hyperparathyroidism (PHPT). We retrospectively compared the surgical outcomes of TEP and open minimally invasive parathyroidectomy (MIP). Methods We analyzed the cases of 28 patients with PHPT who were scheduled to undergo a MIP at Mita Hospital (Tokyo) during the period from April 2015 to March 2019, all of whom were presumed preoperatively to have a single adenoma. Results Eleven of the patients underwent a TEP (10 females, one male; mean age 54.2 years). The other 17 patients underwent an open MIP (11 females, 6 males; mean age 63.5 years). The younger patients and the females tended to select endoscopic surgery as their treatment. The operation time was significantly longer in the TEP group compared to the open MIP group (106 vs. 50 min; P<0.001). Common postoperative complications (such as recurrent laryngeal nerve paralysis and seroma) did not occur in this series. For the TEP patients who did not undergo a partial thyroidectomy, the mean amount of drainage on the first postoperative day was only 19±10 mL. The operative cure rate of the minimally invasive parathyroidectomies was 96.4%. Conclusions TEP is a good surgical procedure for hyperparathyroidism caused by a single adenoma, and it achieves superior cosmetic results without increasing the rate of complications.
Collapse
Affiliation(s)
- Yoshiyuki Saito
- Department of Surgery, International Goodwill Hospital, Yokohama, Kanagawa, Japan.,Department of Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.,Department of Surgery Gastroenterology Center, International University of Health and Welfare, Mita Hospital, Minato-ku, Tokyo, Japan
| | - Yoshifumi Ikeda
- Department of Surgery Gastroenterology Center, International University of Health and Welfare, Mita Hospital, Minato-ku, Tokyo, Japan.,Department of Surgery, International University of Health and Welfare, Atami Hospital, Atami, Shizuoka, Japan
| | - Hiroshi Katoh
- Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
| | - Atsushi Nakao
- Department of Surgery, International Goodwill Hospital, Yokohama, Kanagawa, Japan.,Department of Surgery Gastroenterology Center, International University of Health and Welfare, Mita Hospital, Minato-ku, Tokyo, Japan
| | - Hiroshi Takami
- Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo, Japan
| |
Collapse
|
11
|
Ho K, Saito Y, Ikeda Y, Takami H, Tokuda T, Miyata R, Tomita M, Sato M, Ando N. Remote-access hemithyroidectomy in a patient with papillary thyroid cancer after ipsilateral irradiation: a case report. Gland Surg 2021; 11:622-627. [DOI: 10.21037/gs-21-715] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Accepted: 01/24/2022] [Indexed: 11/06/2022]
|
12
|
Matsuzu K, Sugino K, Masudo K, Mori K, Ono R, Yamazaki H, Masaki C, Akaishi J, Kiyomi Yamada H, Tomoda C, Suzuki A, Uruno T, Ohkuwa K, Kitagawa W, Nagahama M, Takami H, Ito K. Clinical outcomes and risk stratification for papillary thyroid carcinoma presenting with distant metastasis before the era of tyrosine kinase inhibitors. Endocr J 2020; 67:869-876. [PMID: 32350192 DOI: 10.1507/endocrj.ej20-0081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Radioactive iodine (RAI) therapy has been the mainstay of treatment for papillary thyroid carcinoma (PTC) patients with distant metastasis (DM). Although tyrosine kinase inhibitors (TKIs) were introduced for the treatment of RAI refractory metastatic thyroid carcinoma several years ago, clinical outcomes for PTC patients with DM treated using RAI therapy remain unclear. We retrospectively examined 64 PTC patients (9 men, 55 women) with DM at diagnosis treated using RAI therapy without administration of any kind of chemotherapy or TKIs. Median age of patients was 58 years. Site of DM was the lungs (n = 59), bone (n = 3), and pleural dissemination (n = 2). No patients showed multiple-organ metastases at diagnosis. By the end of the study period, 21 patients had died of PTC. Cause-specific survival rates at 10, 15, and 20 years after initial surgery were 68.2%, 63.6% and 61.1%, respectively. Uni- and multivariate analyses identified age ≥55 years (HR 3.1, p = 0.023), site of DM other than the lungs (HR 13.4, p < 0.0001), and DM with no RAI avidity (HR 5.1, p = 0.0098) as factors independently associated with disease-related death. When analyses were restricted to patients with lung metastasis (n = 59), surgical non-curability was another independent risk factor (HR 5.2, p = 0.0047) in addition to age and RAI avidity. According to risk stratification analysis based on these risk factors, patients with site of DM other than the lungs or with lung metastasis showing ≥2 risk factors among age ≥55 years, DM with no RAI avidity, and surgical non-curability are expected to show higher mortality rates.
Collapse
Affiliation(s)
| | | | - Katsuhiko Masudo
- Department of Surgery, Yokohama City University Hospital, Kanagawa 236-0004, Japan
| | - Kazunori Mori
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | - Reiko Ono
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | - Haruhiko Yamazaki
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
- Department of Surgery, Yokohama City University Hospital, Kanagawa 236-0004, Japan
| | - Chie Masaki
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | - Junko Akaishi
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | | | - Chisato Tomoda
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | - Akifumi Suzuki
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | - Takashi Uruno
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | - Keiko Ohkuwa
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | | | | | - Hiroshi Takami
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| | - Koichi Ito
- Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan
| |
Collapse
|
13
|
Yamada S, Fujii T, Yamamoto T, Takami H, Yoshioka I, Yamaki S, Sonohara F, Shibuya K, Motoi F, Hirano S, Murakami Y, Inoue H, Hayashi M, Murotani K, Kitayama J, Ishikawa H, Kodera Y, Sekimoto M, Satoi S. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Br J Surg 2020; 107:1811-1817. [PMID: 32638367 PMCID: PMC7689756 DOI: 10.1002/bjs.11792] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2020] [Revised: 04/27/2020] [Accepted: 05/19/2020] [Indexed: 12/12/2022]
Abstract
BACKGROUND Intraperitoneal chemotherapy using paclitaxel is considered an experimental approach for treating peritoneal carcinomatosis. This study aimed to determine the recommended dose, and to evaluate the clinical efficacy and safety, of the combination of intravenous gemcitabine, intravenous nab-paclitaxel and intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. METHODS The frequencies of dose-limiting toxicities were evaluated, and the recommended dose was determined in phase I. The primary endpoint of the phase II analysis was overall survival rate at 1 year. Secondary endpoints were antitumour effects, symptom-relieving effects, safety and overall survival. RESULTS The recommended doses of intravenous gemcitabine, intravenous nab-paclitaxel and intraperitoneal paclitaxel were 800, 75 and 20 mg/m2 respectively. Among 46 patients enrolled in phase II, the median time to treatment failure was 6·0 (range 0-22·6) months. The response and disease control rates were 21 of 43 and 41 of 43 respectively. Ascites disappeared in 12 of 30 patients, and cytology became negative in 18 of 46. The median survival time was 14·5 months, and the 1-year overall survival rate was 61 per cent. Conversion surgery was performed in eight of 46 patients, and those who underwent resection survived significantly longer than those who were not treated surgically (median survival not reached versus 12·4 months). Grade 3-4 haematological toxicities developed in 35 of 46 patients, whereas non-haematological adverse events occurred in seven patients. CONCLUSION Adding intraperitoneal paclitaxel had clinical efficacy with acceptable tolerability.
Collapse
Affiliation(s)
- S Yamada
- Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Fujii
- Department of Surgery and Science Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
| | - T Yamamoto
- Department of Surgery, Kansai Medical University, Hirakata, Japan
| | - H Takami
- Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - I Yoshioka
- Department of Surgery and Science Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
| | - S Yamaki
- Department of Surgery, Kansai Medical University, Hirakata, Japan
| | - F Sonohara
- Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - K Shibuya
- Department of Surgery and Science Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
| | - F Motoi
- Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - S Hirano
- Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Y Murakami
- Department of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo, Japan
| | - H Inoue
- Department of Hepatobiliary-pancreatic and Breast Surgery, Ehime University Graduate School of Medicine, Ehime, Fukuoka, Japan
| | - M Hayashi
- Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - K Murotani
- Biostatistics Centre, Graduate School of Medicine, Kurume University, Fukuoka, Japan
| | - J Kitayama
- Department of Gastrointestinal Surgery, Jichi Medical University, Tochigi, Japan
| | - H Ishikawa
- Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Y Kodera
- Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Sekimoto
- Department of Surgery, Kansai Medical University, Hirakata, Japan
| | - S Satoi
- Department of Surgery, Kansai Medical University, Hirakata, Japan
| |
Collapse
|
14
|
Saito Y, Kawakubo H, Takami H, Aoyama J, Mayanagi S, Irino T, Fukuda K, Suda K, Nakamura R, Wada N, Kitagawa Y. Thyroid and Parathyroid Functions After Pharyngo-Laryngo-Esophagectomy for Cervical Esophageal Cancer. Ann Surg Oncol 2019; 26:3711-3717. [PMID: 31187362 DOI: 10.1245/s10434-019-07476-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Indexed: 09/13/2023]
Abstract
BACKGROUND Cervical esophageal cancer (CEC) patients whose larynx function cannot be preserved often undergo chemoradiotherapy, whereas those with residual or recurrent lesions undergo a pharyngo-laryngo-esophagectomy (PLE); however, some need to undergo a pharyngolaryngectomy with total esophagectomy (PLTE) for synchronous or metachronous esophageal cancer. We retrospectively evaluated the relationship between preoperative irradiation (or the extent of esophageal resection) and postoperative endocrine complications in CEC, including hypothyroidism and hypoparathyroidism. METHODS The cancers of 35 (5.4%) of 678 esophageal cancer patients with esophagectomy treated in 2000-2017 were CECs. We also analyzed the 17 cases of CEC patients who underwent PLE with thyroid lobectomy-11 with irradiation before PLE and 6 without irradiation. Seven patients underwent a PLTE. RESULTS Hypothyroidism and hypoparathyroidism occurred in 14 and 12 patients, respectively. The hypothyroidism rate was significantly higher in patients with irradiation versus those without irradiation (100% vs. 50%; p = 0.010), and the hypoparathyroidism rate was significantly higher in the PLTE versus non-PLTE patients (100% vs. 50%; p = 0.026). The mean levothyroxine dosage was 1.60 μg/kg/day in the PLE patients post-irradiation. CONCLUSIONS Irradiation appears to be a risk factor for hypothyroidism after PLE with thyroid lobectomy, while PLTE might have some effect on hypoparathyroidism. Due to vocal function loss, PLE patients may experience symptoms from endocrine complications. Levothyroxine treatment soon after PLE for post-irradiation patients and patients requiring as-needed calcium or vitamin D supplementation based on biochemical hypocalcemia for PLE (especially PLTE), may be effective in preventing symptomatic endocrine complications.
Collapse
Affiliation(s)
- Yoshiyuki Saito
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
| | - Hirofumi Kawakubo
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan.
| | | | - Junya Aoyama
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
| | - Shuhei Mayanagi
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
| | - Tomoyuki Irino
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
| | - Kazumasa Fukuda
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
| | - Koichi Suda
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
- Division of Upper GI, Department of Surgery, Fujita Health University, Toyoake, Aichi, Japan
| | - Rieko Nakamura
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
| | - Norihito Wada
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
| | - Yuko Kitagawa
- Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
| |
Collapse
|
15
|
Saito Y, Matsuzu K, Sugino K, Takami H, Kitagawa W, Nagahama M, Ito K. The impact of completion thyroidectomy followed by radioactive iodine ablation for patients with lymph node recurrence of papillary thyroid carcinoma. Surgery 2019; 166:342-348. [DOI: 10.1016/j.surg.2019.04.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Revised: 03/29/2019] [Accepted: 04/16/2019] [Indexed: 11/28/2022]
|
16
|
Nozaka H, Sazawa H, Ozaki E, Nakano M, Takami H. Detection Algorithm for Inadequate Blood Specimens Due to Contamination with an Infusion Solution in the Clinical Chemistry Tests: Prevention of Incidents by Blood Draw Error. Stud Health Technol Inform 2019; 264:1867-1869. [PMID: 31438383 DOI: 10.3233/shti190688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
The aim of this work is to study the influence of contamination with infusion in clinical chemistry tests and to design an algorithm for detection of inadequate blood specimen. We show that panic value of postassium (K+)/ glucose (GLU) or decrease of total protein (TP), albumin (ALB), urea nitrogen (BUN), uric acid (UA), high-density lipoprotein cholesterol (HDL-C), total cholesterol (T-CHO), and calcium (Ca) is an index of contamination of drip infusion solution. Through a clinical study, we show that our algorithm is useful for preventing adverse medical errors.
Collapse
Affiliation(s)
- H Nozaka
- Hirosaki University Graduate School of Health Sciences, Hirosaki City, Aomori, Japan
| | - H Sazawa
- Department of Clinical Labolatory, Hokkaido Cancer Center, Sapporo City, Hokkaido, Japan
| | - E Ozaki
- Hirosaki University Graduate School of Health Sciences, Hirosaki City, Aomori, Japan
| | - M Nakano
- Hirosaki University Graduate School of Health Sciences, Hirosaki City, Aomori, Japan
| | - H Takami
- Hirosaki University Graduate School of Health Sciences, Hirosaki City, Aomori, Japan
| |
Collapse
|
17
|
Nozaka H, Sazawa H, Shiroto S, Nakano M, Takami H. Development of Albumin Analyzer with Whole Blood and Application to Telemedicine for Patient Nutrition Management in Home Health Nursing. Stud Health Technol Inform 2019; 264:1745-1746. [PMID: 31438323 DOI: 10.3233/shti190627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Albumin level is q significant indicator of patient nutritional status. However, Point of Care Testing (POCT) devices and telemedicine system that nurses can operate easily in-home medical care is not developed. The aim of this work is the development of a POCT device for Albumin level and application to a telemedicine support system. The operability of our system was simple and easy for the nurse or patient. We believe our method is useful for Nutrition Support Team activities in-home medical care.
Collapse
Affiliation(s)
- H Nozaka
- Hirosaki University Graduate school of Health Sciences, Hirosaki city, Aomori, Japan
| | - H Sazawa
- Department of Clinical Labolatory, Hokkaido Cancer Center, Sapporo city, Hokkaido, Japan
| | - S Shiroto
- Hirosaki University Graduate school of Health Sciences, Hirosaki city, Aomori, Japan
| | - M Nakano
- Hirosaki University Graduate school of Health Sciences, Hirosaki city, Aomori, Japan
| | - H Takami
- Hirosaki University Graduate school of Health Sciences, Hirosaki city, Aomori, Japan
| |
Collapse
|
18
|
Takami H, Fukushima S, Aoki K, Satomi K, Narumi K, Hama N, Matsushita Y, Fukuoka K, Yamasaki K, Nakamura T, Mukasa A, Saito N, Suzuki T, Yanagisawa T, Nakamura H, Sugiyama K, Tamura K, Maehara T, Nakada M, Nonaka M, Asai A, Yokogami K, Takeshima H, Iuchi T, Kanemura Y, Kobayashi K, Nagane M, Kurozumi K, Yoshimoto K, Matsuda M, Matsumura A, Hirose Y, Tokuyama T, Kumabe T, Ueki K, Narita Y, Shibui S, Totoki Y, Shibata T, Nakazato Y, Nishikawa R, Matsutani M, Ichimura K. Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance. Neuropathol Appl Neurobiol 2019; 46:111-124. [PMID: 31179566 DOI: 10.1111/nan.12570] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Accepted: 06/03/2019] [Indexed: 12/13/2022]
Abstract
AIMS Alterations in microenvironments are a hallmark of cancer, and these alterations in germinomas are of particular significance. Germinoma, the most common subtype of central nervous system germ cell tumours, often exhibits massive immune cell infiltration intermingled with tumour cells. The role of these immune cells in germinoma, however, remains unknown. METHODS We investigated the cellular constituents of immune microenvironments and their clinical impacts on prognosis in 100 germinoma cases. RESULTS Patients with germinomas lower in tumour cell content (i.e. higher immune cell infiltration) had a significantly longer progression-free survival time than those with higher tumour cell contents (P = 0.03). Transcriptome analyses and RNA in-situ hybridization indicated that infiltrating immune cells comprised a wide variety of cell types, including lymphocytes and myelocyte-lineage cells. High expression of CD4 was significantly associated with good prognosis, whereas elevated nitric oxide synthase 2 was associated with poor prognosis. PD1 (PDCD1) was expressed by immune cells present in most germinomas (93.8%), and PD-L1 (CD274) expression was found in tumour cells in the majority of germinomas examined (73.5%). CONCLUSIONS The collective data strongly suggest that infiltrating immune cells play an important role in predicting treatment response. Further investigation should lead to additional categorization of germinoma to safely reduce treatment intensity depending on tumour/immune cell balance and to develop possible future immunotherapies.
Collapse
Affiliation(s)
- H Takami
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.,Department of Neurosurgery, Faculty of Medicine, The University of Tokyo Hospital, Tokyo, Japan
| | - S Fukushima
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - K Aoki
- Division of Gene and Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan
| | - K Satomi
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.,Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
| | - K Narumi
- Division of Gene and Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan
| | - N Hama
- Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan
| | - Y Matsushita
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.,Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - K Fukuoka
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.,Division of Pediatric Neuro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan
| | - K Yamasaki
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.,Department of Pediatrics, Osaka City General Hospital, Osaka, Japan
| | - T Nakamura
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.,Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Kanagawa, Japan
| | - A Mukasa
- Department of Neurosurgery, Faculty of Medicine, The University of Tokyo Hospital, Tokyo, Japan.,Department of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
| | - N Saito
- Department of Neurosurgery, Faculty of Medicine, The University of Tokyo Hospital, Tokyo, Japan
| | - T Suzuki
- Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Saitama, Japan
| | - T Yanagisawa
- Division of Pediatric Neuro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan
| | - H Nakamura
- Department of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.,Department of Neurosurgery, Kurume University, Fukuoka, Japan
| | - K Sugiyama
- Department of Neurosurgery, Faculty of Medicine, Hiroshima University, Hiroshima, Japan
| | - K Tamura
- Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - T Maehara
- Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - M Nakada
- Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan
| | - M Nonaka
- Department of Neurosurgery, Kansai Medical University Hospital, Osaka, Japan
| | - A Asai
- Department of Neurosurgery, Kansai Medical University Hospital, Osaka, Japan
| | - K Yokogami
- Department of Neurosurgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
| | - H Takeshima
- Department of Neurosurgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
| | - T Iuchi
- Department of Neurosurgery, Chiba Cancer Center, Chiba, Japan
| | - Y Kanemura
- Department of Neurosurgery, Osaka National Hospital, National Hospital Organization, Osaka, Japan.,Department of Biomedical Research and Innovation, Institute for Clinical Research, Osaka National Hospital, National Hospital Organization, Osaka, Japan
| | - K Kobayashi
- Department of Neurosurgery, Faculty of Medicine, Kyorin University, Tokyo, Japan
| | - M Nagane
- Department of Neurosurgery, Faculty of Medicine, Kyorin University, Tokyo, Japan
| | - K Kurozumi
- Department of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan
| | - K Yoshimoto
- Department of Neurosurgery, Kyusyu University Hospital, Fukuoka, Japan
| | - M Matsuda
- Department of Neurosurgery, University of Tsukuba Hospital, Ibaraki, Japan
| | - A Matsumura
- Department of Neurosurgery, University of Tsukuba Hospital, Ibaraki, Japan
| | - Y Hirose
- Department of Neurosurgery, Fujita Health University Hospital, Aichi, Japan
| | - T Tokuyama
- Department of Neurosurgery, Hamamatsu University Hospital, Shizuoka, Japan
| | - T Kumabe
- Department of Neurosurgery, Kitasato University, Kanagawa, Japan
| | - K Ueki
- Department of Neurosurgery, Dokkyo Medical Univeristy, Tochigi, Japan
| | - Y Narita
- Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - S Shibui
- Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Y Totoki
- Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan
| | - T Shibata
- Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan
| | - Y Nakazato
- Department of Pathology, Hidaka Hospital, Gunma, Japan
| | - R Nishikawa
- Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Kanagawa, Japan
| | - M Matsutani
- Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Kanagawa, Japan
| | - K Ichimura
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | | |
Collapse
|
19
|
Tahara M, Takami H, Ito Y, Sugino K, Takahashi S, Takeyama H, Tsutsui H, Hara H, Mitsuma A, Yamashita H, Okamoto T, Sugitani I, Ohashi Y, Imai T. Cohort study exploring the effect of lenvatinib on differentiated thyroid cancer. Endocr J 2018; 65:1071-1074. [PMID: 30369531 DOI: 10.1507/endocrj.ej18-0261] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Lenvatinib is a molecular-targeting agent that was recently approved in Japan for treatment of curatively unresectable, radioactive iodine-refractory, progressive differentiated thyroid cancer (DTC). Because only a few Japanese patients have received lenvatinib in clinical trials, there are limited domestic data on its safety and efficacy or prognostic factors. Therefore, a prospective observational study has been designed to collect safety and efficacy data in at least 300 patients with curatively unresectable DTC receiving lenvatinib therapy (24 mg/day), in order to find predictors of antitumor activity and survival. Patients with progressive curatively unresectable DTC refractory to radioiodine therapy will be enrolled and the primary endpoint will be overall survival. This study is designed to estimate the 95% confidence intervals of the 1-year and 2-year survival rates with a two-sided width of less than 10%. Secondary endpoints will be the time to treatment failure, time to strategy failure, progression-free survival time with clinical progressive disease, response rate, quality of life, safety, and patient reports. The ultimate goal is to obtain information for developing evidence-based guidelines for treatment of DTC, including recommendations on patient selection, dosages, and duration of treatment. This study has been registered with the UMIN Clinical Trials Registry (UMIN000022243).
Collapse
Affiliation(s)
- Makoto Tahara
- Department of Head and Neck Cancer Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan
| | - Hiroshi Takami
- Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo 150-8308, Japan
| | - Yasuhiro Ito
- Department of Clinical Trial, Department of Surgery, Kuma Hospital, Kobe, Hyogo 650-0011, Japan
| | - Kiminori Sugino
- Department of Surgery, Ito Hospital, Shibuya-ku, Tokyo 150-8308, Japan
| | - Shunji Takahashi
- Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan
| | - Hiroshi Takeyama
- Department of Breast and Endocrine Surgery, The Jikei University School of Medicine, Minato-ku, Tokyo 105-8461, Japan
| | - Hidemitsu Tsutsui
- Department of Thoracic and Thyroid Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, Japan
| | - Hisato Hara
- Department of Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8576, Japan
| | - Ayako Mitsuma
- Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Aichi 466-8560, Japan
| | - Hiroyuki Yamashita
- Department of Surgery, Yamashita Thyroid Hospital, Fukuoka 812-0034, Japan
| | - Takahiro Okamoto
- Department of Breast and Endocrine Surgery, Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo 162-8666, Japan
| | - Iwao Sugitani
- Department of Endocrine Surgery, Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8603, Japan
| | - Yasuo Ohashi
- Department of Integrated Science and Engineering for Sustainable Society, Chuo University, Bunkyo-ku, Tokyo 112-8551, Japan
| | - Tsuneo Imai
- National Hospital Organization, Higashinagoya National Hospital, Nagoya, Aichi 465-8620, Japan
| |
Collapse
|
20
|
Saito Y, Sugino K, Takami H, Matsuzu K, Uruno T, Ohkuwa K, Kitagawa W, Nagahama M, Kawakubo H, Ito K, Kitagawa Y. Clinical Status and Treatment of Liver Metastasis of Differentiated Thyroid Cancer Using Tyrosine Kinase Inhibitors. World J Surg 2018; 42:3632-3637. [PMID: 29766229 DOI: 10.1007/s00268-018-4676-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND Treatment of patients with liver metastasis of differentiated thyroid carcinoma (DTC) has not been sufficiently defined, because liver metastasis of DTC has been described mostly as case reports. Additionally, such patients are considered end-of-treatment responders. A relatively new approach using tyrosine kinase inhibitors (TKIs) may provide opportunities to manage systemic metastasis. This study aims to define the clinical features of DTC patients with liver metastasis and evaluate the benefits of TKIs. METHODS We retrospectively analyzed clinical features of 29 patients (mean age 67.8 years) diagnosed with liver metastasis of DTC at our institution between January 1981 and May 2017. RESULTS All patients had distant metastasis at other organ sites upon diagnosis of liver metastasis; 41% of them developed new metastasis afterward. Management after diagnosis of liver metastasis comprised palliative care (48%), radioactive iodine therapy (28%), and TKI therapy (24%). The median survival after diagnosis of liver metastasis was only 4.8 months. Survival rates were significantly better in patients with performance statuses between 0 and 2 on the Eastern Cooperative Oncology Group scale at diagnosis of liver metastasis (n = 22, 76%) treated with TKI compared to those who were not (P = 0.017; log-rank test; hazard ratio 0.19). One-year survival rates were 71.4 and 26.7% for patients treated with or without TKI, respectively. CONCLUSIONS Patients with liver metastasis had poor clinical prognosis. When other distant metastases existed at diagnosis of liver metastasis, TKI therapy was considered an effective therapeutic option for patients with liver metastasis of DTC.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Carcinoma, Papillary, Follicular/drug therapy
- Carcinoma, Papillary, Follicular/mortality
- Carcinoma, Papillary, Follicular/pathology
- Female
- Humans
- Liver Neoplasms/drug therapy
- Liver Neoplasms/mortality
- Liver Neoplasms/secondary
- Male
- Middle Aged
- Phenylurea Compounds/therapeutic use
- Protein-Tyrosine Kinases/therapeutic use
- Quinolines/therapeutic use
- Retrospective Studies
- Thyroid Cancer, Papillary/drug therapy
- Thyroid Cancer, Papillary/mortality
- Thyroid Cancer, Papillary/pathology
- Thyroid Neoplasms/mortality
- Thyroid Neoplasms/pathology
Collapse
Affiliation(s)
- Yoshiyuki Saito
- Department of Surgery, Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo, 150-8308, Japan
- Department of Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Kiminori Sugino
- Department of Surgery, Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo, 150-8308, Japan.
| | - Hiroshi Takami
- Department of Surgery, Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo, 150-8308, Japan
| | - Kenichi Matsuzu
- Department of Surgery, Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo, 150-8308, Japan
| | - Takashi Uruno
- Department of Surgery, Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo, 150-8308, Japan
| | - Keiko Ohkuwa
- Department of Surgery, Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo, 150-8308, Japan
| | - Wataru Kitagawa
- Department of Surgery, Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo, 150-8308, Japan
| | - Mitsuji Nagahama
- Department of Surgery, Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo, 150-8308, Japan
| | - Hirofumi Kawakubo
- Department of Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| | - Koichi Ito
- Department of Surgery, Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo, 150-8308, Japan
| | - Yuko Kitagawa
- Department of Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
| |
Collapse
|
21
|
Muraoka Y, Sonoda S, Inoue K, Miura T, Shimizu A, Takami H, Sanuki Y, Anai R, Tsuda Y, Araki M, Otsuji Y. P6484Association between in-stent neoatherosclerosis and plaque progression in non-culprit lesions after cobalt-chromium everolimus-eluting stents implantation: five-year follow-up OCT study. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Y Muraoka
- University of Occupational and Environmental Health, cardiovascular medicine, Kitakyusyu, Japan
| | - S Sonoda
- University of Occupational and Environmental Health, cardiovascular medicine, Kitakyusyu, Japan
| | - K Inoue
- University of Occupational and Environmental Health, cardiovascular medicine, Kitakyusyu, Japan
| | - T Miura
- University of Occupational and Environmental Health, cardiovascular medicine, Kitakyusyu, Japan
| | - A Shimizu
- University of Occupational and Environmental Health, cardiovascular medicine, Kitakyusyu, Japan
| | - H Takami
- University of Occupational and Environmental Health, cardiovascular medicine, Kitakyusyu, Japan
| | - Y Sanuki
- University of Occupational and Environmental Health, cardiovascular medicine, Kitakyusyu, Japan
| | - R Anai
- University of Occupational and Environmental Health, cardiovascular medicine, Kitakyusyu, Japan
| | - Y Tsuda
- University of Occupational and Environmental Health, cardiovascular medicine, Kitakyusyu, Japan
| | - M Araki
- University of Occupational and Environmental Health, cardiovascular medicine, Kitakyusyu, Japan
| | - Y Otsuji
- University of Occupational and Environmental Health, cardiovascular medicine, Kitakyusyu, Japan
| |
Collapse
|
22
|
Shimizu A, Sonoda S, Miura T, Takami H, Anai R, Muraoka Y, Sanuki Y, Tsuda Y, Araki M, Otsuji Y. P2680Long-term prognosis after dual antiplatelet therapy in hemodialysis patients following percutaneous coronary intervention with second-generation drug eluting stent. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- A Shimizu
- University of Occupational and Environmental Health, Cardiovascular Medicine, Kitakyushu, Japan
| | - S Sonoda
- University of Occupational and Environmental Health, Cardiovascular Medicine, Kitakyushu, Japan
| | - T Miura
- University of Occupational and Environmental Health, Cardiovascular Medicine, Kitakyushu, Japan
| | - H Takami
- University of Occupational and Environmental Health, Cardiovascular Medicine, Kitakyushu, Japan
| | - R Anai
- University of Occupational and Environmental Health, Cardiovascular Medicine, Kitakyushu, Japan
| | - Y Muraoka
- University of Occupational and Environmental Health, Cardiovascular Medicine, Kitakyushu, Japan
| | - Y Sanuki
- University of Occupational and Environmental Health, Cardiovascular Medicine, Kitakyushu, Japan
| | - Y Tsuda
- University of Occupational and Environmental Health, Cardiovascular Medicine, Kitakyushu, Japan
| | - M Araki
- University of Occupational and Environmental Health, Cardiovascular Medicine, Kitakyushu, Japan
| | - Y Otsuji
- University of Occupational and Environmental Health, Cardiovascular Medicine, Kitakyushu, Japan
| |
Collapse
|
23
|
Kanda M, Shimizu D, Tanaka H, Tanaka C, Kobayashi D, Hayashi M, Takami H, Niwa Y, Yamada S, Fujii T, Sugimoto H, Kodera Y. Synaptotagmin XIII expression and peritoneal metastasis in gastric cancer. Br J Surg 2018; 105:1349-1358. [PMID: 29741294 DOI: 10.1002/bjs.10876] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2017] [Revised: 02/11/2018] [Accepted: 03/16/2018] [Indexed: 12/11/2022]
Abstract
BACKGROUND Peritoneal metastasis is a frequent cause of death in patients with gastric cancer. The aim of this study was to identify molecules responsible for mediating peritoneal metastasis of gastric cancer. METHODS Transcriptome and bioinformatics analyses were conducted to identify molecules associated with peritoneal metastasis. The therapeutic effects of intraperitoneally administered small interfering (si) RNA were evaluated using mouse xenograft models. Expression of mRNA and protein was determined in gastric tissues from patients with gastric cancer. RESULTS Synaptotagmin XIII (SYT13) was expressed at significantly higher levels in patients with peritoneal recurrence, but not in those with hepatic or distant lymph node recurrence. Inhibition of SYT13 expression in a gastric cancer cell line transfected with SYT13-specific siRNA (siSYT13) was associated with decreased invasion and migration ability of the cells, but not with proliferation and apoptosis. Intraperitoneal administration of siSYT13 significantly inhibited the growth of peritoneal nodules and prolonged survival in mice. In an analysis of 200 patients with gastric cancer, SYT13 expression in primary gastric cancer tissues was significantly greater in patients with peritoneal recurrence or metastasis. A high level of SYT13 expression in primary gastric cancer tissues was an independent risk factor for peritoneal recurrence. CONCLUSION SYT13 expression in gastric cancer is associated with perioneal metatases and is a potential target for treatment.
Collapse
Affiliation(s)
- M Kanda
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - D Shimizu
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Tanaka
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - C Tanaka
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - D Kobayashi
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Hayashi
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Takami
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Niwa
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Yamada
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Fujii
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Sugimoto
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Kodera
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
24
|
Okunaga A, Oshima Y, Yasui I, Ikuma S, Higashidani N, Takashima S, Kita H, Hiramoto Y, Kuroda T, Morimoto S, Sasaki S, Takami H, Izumi M. Great Saphenous Vein Flow Pattern as a Simple Ultrasonographic Sign of Early Recanalization of Deep Vein Thrombosis: A Case Series Report. Ann Vasc Dis 2018; 11:130-133. [PMID: 29682121 PMCID: PMC5882343 DOI: 10.3400/avd.cr.17-00096] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
We retrospectively examined patients with ultrasonographically occlusive acute proximal deep vein thrombosis (DVT). All patients were categorized into two groups on the basis of whether great saphenous vein (GSV) flow toward the common femoral vein was detected (flow [+]; n=10) or undetected (flow [−]; n=10). We investigated the relationship between the GSV flow pattern and DVT recanalization. Thrombus recanalization, which is defined as diameter reduction to lower than 40% of the vessel diameter, was confirmed in seven of the flow (+), and none of the flow (−). This study proposes that the GSV flow pattern may be a simple marker for the recanalization of proximal occlusive DVT.
Collapse
Affiliation(s)
- Akiko Okunaga
- Department of Clinical Laboratory, Kinki Central Hospital
| | | | - Isao Yasui
- Department of Clinical Laboratory, Kinki Central Hospital
| | - Saki Ikuma
- Department of Cardiology, Kinki Central Hospital
| | | | | | - Hisaaki Kita
- Department of Cardiology, Kinki Central Hospital
| | | | | | | | - Shinji Sasaki
- Department of Clinical Laboratory, Kinki Central Hospital
| | | | | |
Collapse
|
25
|
Tanaka Y, Kanda M, Tanaka C, Kobayashi D, Tanaka H, Takami H, Hayashi M, Iwata N, Niwa Y, Yamada S, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Involvement of the immunoregulator MZB1 in progression of gastric cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Masaki C, Sugino K, Saito N, Saito Y, Tanaka T, Ogimi Y, Maeda T, Osaku T, Akaishi J, Hames KY, Tomoda C, Suzuki A, Matsuzu K, Uruno T, Ohkuwa K, Kitagawa W, Nagahama M, Takami H, Ito K. Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma. Endocr J 2017; 64:819-826. [PMID: 28659544 DOI: 10.1507/endocrj.ej17-0104] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Although advanced thyroid carcinoma patients who cannot be cured by conventional therapy have lacked effective treatment, multitargeted tyrosine kinase inhibitors have recently become available. Phase 3 trials of lenvatinib showed a median time to objective response of 2 (95 % confidence interval (CI) 1.9-3.5) months, demonstrating that shrinks tumors rapidly. The phenomenon of immediate tumor shrink is known as early tumor shrinkage (ETS) which is related to clinical outcome in other malignancies. However, precisely when within 8 weeks lenvatinib starts to affect tumors remains unclear. In tumors near the carotid arteries, trachea, or esophagus, a rapid therapeutic effect can induce fistula formation or arterial bleeding. To prevent such treatment-emergent serious adverse events (SAE), early imaging evaluation seems to be very important. In this study, the point in time when lenvatinib started to shrink tumors was retrospectively investigated. The subjects were 16 patients who started lenvatinib administration between May and August 2015. Tumor size was evaluated by computed tomography (CT) scans frequently within the first 8 weeks according to the Response Evaluation Criteria In Solid Tumors (RECIST) guideline. Initial tumor response was defined as ≥ 10% tumor reduction. Serum thyroglobulin (Tg) level was monitored in 8 differentiated thyroid carcinoma (DTC) without TgAb patients. At the first evaluation, 13 patients (83.3 %) showed tumor reduction and that decreased with time. Thirteen patients (83.3 %) showed >10 % tumor reduction within 8 weeks. In all DTC patients, serum Tg level was markedly decreased. In conclusion, lenvatinib immediately shrinks tumors, the so-called ETS phenomenon. Therefore, careful attention should be paid to fistula formation from the early phase.
Collapse
MESH Headings
- Adenocarcinoma, Follicular/diagnostic imaging
- Adenocarcinoma, Follicular/drug therapy
- Adenocarcinoma, Follicular/pathology
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents/therapeutic use
- Carcinoma, Medullary/diagnostic imaging
- Carcinoma, Medullary/drug therapy
- Carcinoma, Medullary/pathology
- Carcinoma, Papillary/diagnostic imaging
- Carcinoma, Papillary/drug therapy
- Carcinoma, Papillary/pathology
- Female
- Humans
- Male
- Middle Aged
- Phenylurea Compounds/therapeutic use
- Quinolines/therapeutic use
- Thyroid Gland/diagnostic imaging
- Thyroid Gland/pathology
- Thyroid Neoplasms/diagnostic imaging
- Thyroid Neoplasms/drug therapy
- Thyroid Neoplasms/pathology
- Tomography, X-Ray Computed
- Treatment Outcome
Collapse
Affiliation(s)
- Chie Masaki
- Department of Surgery, Ito Hospital, Tokyo, Japan
| | | | - Naoko Saito
- Department of Diagnostic Radiology, Saitama Medical University, International Medical Center, Hidaka, Japan
| | | | | | - Yuna Ogimi
- Department of Surgery, Ito Hospital, Tokyo, Japan
| | | | | | | | | | | | | | | | | | - Keiko Ohkuwa
- Department of Surgery, Ito Hospital, Tokyo, Japan
| | | | | | | | - Koichi Ito
- Department of Surgery, Ito Hospital, Tokyo, Japan
| |
Collapse
|
27
|
Sanuki Y, Shinjo S, Shimizu A, Takami H, Anai R, Muraoka Y, Tsuda Y, Araki M, Otsuji Y. P517Contribution of post-stent irregular protrusion to in-stent neoatheroscrelosis after second-generation drug-eluting stent implantation. - Optical coherence tomography study-. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Shimizu A, Sonoda S, Takami H, Anai R, Muraoka Y, Sanuki Y, Tsuda Y, Araki M, Otsuji Y. P1661Impact of hemorrhagic events during dual antiplatelet therapy after drug-eluting stent implantation in patients with hemodialysis. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Takami H, Sonoda S, Shimizu A, Anai R, Muraoka Y, Sanuki Y, Tsuda Y, Araki M, Otsuji Y. P1801Comparison between minimum lumen area and integrated backscatter intravascular ultrasound derived intraluminal ultrasonic intensity for detecting functionally significant coronary artery stenosis. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Muraoka Y, Sonoda S, Shimizu A, Takami H, Anai R, Sanuki Y, Tsuda Y, Araki M, Otsuji Y. P666Efficacy of optical coherence tomography based vulnerable plaque assessment at the index PCI to predict remote plaque progression in non-culprit lesions. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Oya H, Kanda M, Koike M, Iwata N, Niwa Y, Shimizu D, Takami H, Sueoka S, Hashimoto R, Ezaka K, Nomoto S, Yamada S, Fujii T, Nakayama G, Sugimoto H, Fujiwara M, Kodera Y. Detection of serum melanoma-associated antigen D4 in patients with squamous cell carcinoma of the esophagus. Dis Esophagus 2016; 29:663-9. [PMID: 25951896 DOI: 10.1111/dote.12373] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Despite improvements in surgical techniques, perioperative management, and multidisciplinary therapy, treatment outcomes of patients with esophageal squamous cell carcinoma (ESCC) remain poor. Therefore, development of novel molecular biomarkers, which either predict patient survival or become therapeutic targets, is urgently required. In the present study, to facilitate early detection of ESCC and predict its clinical course, we investigated the relationship of the serum level of melanoma-associated antigen (MAGE)-D4 to patients' clinicopathological characteristics. Using quantitative real-time reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assays, we determined the levels of MAGE-D4 mRNA and protein in cell lysates and conditioned medium of cultures, respectively, of nine ESCC cell lines. Further, we determined MAGE-D4 levels in serum samples collected from 44 patients with ESCC who underwent radical esophagectomy without neoadjuvant therapy as well as from 40 healthy volunteers. Samples of conditioned medium and cell lysates contained comparable levels of MAGE-D4 that correlated closely with the levels of MAGE-D4 mRNA. Preoperative MAGE-D4 levels in the sera of 44 patients with ESCC, which varied from 0 to 2,354 pg/mL (314 ± 505 pg/mL, mean ± standard deviation), were significantly higher compared with those of healthy volunteers. By setting the cutoff at the highest value for healthy volunteers (50 pg/mL), the MAGE-D4-positive group of patients was more likely to have shorter disease-specific and disease-free survival compared with those of the MAGE-D4-negative group, although the differences were not statistically significant. Our results indicate that the elevation of preoperative serum MAGE-D4 levels in some patients with ESCC was possibly caused by excess production of MAGE-D4 by tumor cells followed by its release into the circulation. Clinical implications of serum MAGE-D4 levels should be validated in a large population of patients with ESCC.
Collapse
Affiliation(s)
- H Oya
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Kanda
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Koike
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - N Iwata
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Niwa
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - D Shimizu
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Takami
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Sueoka
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - R Hashimoto
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - K Ezaka
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Nomoto
- Department of Surgery, Aichi-Gakuin University School of Dentistry, Nagoya, Japan
| | - S Yamada
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Fujii
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - G Nakayama
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - H Sugimoto
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Fujiwara
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Kodera
- Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
32
|
Oshima Y, Rin S, Kita H, Hiramoto Y, Morimoto S, Okunaga A, Takami H, Nakamura S, Saito H, Izumi M. The Frequency of Fish-Eating Could Negatively Associate with Visceral Adiposity in Those Who Eat Moderately. J Nutr Sci Vitaminol (Tokyo) 2015; 61:426-31. [PMID: 26639852 DOI: 10.3177/jnsv.61.426] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Visceral fat accumulation is regarded as one of the major phenotypes of metabolic syndrome. There have not been enough data on the relationship between the fish-eating habit and visceral adiposity. A total of 94 male participants received abdominal CT for the measurement of the visceral fat area (VFA), serum sampling for the fatty acid composition and questionnaires about their life-style. We divided the participants into two groups: whether they ate their fill (group F, n=70) or they ate in moderation (group M, n=24). Stepwise multiple linear regression analyses showed that usual alcohol consumption and lower daily physical activity in group F, and infrequent fish-eating and frequent fat-rich deserts in group M were the significant positive correlates with the VFA. The serum eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratio showed significant correlation with the frequency of fish-eating in both groups. Interestingly, in group M, the serum EPA/AA ratio negatively correlated with the VFA, while it failed in group F. In conclusion, the present data suggest that the fish-eating habit might negatively associate with visceral fat accumulation only in those who are moderate in eating in the general population.
Collapse
Affiliation(s)
- Yuichi Oshima
- Division of Cardiology, Department of Internal Medicine
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Takami H, Ito Y, Okamoto T, Onoda N, Noguchi H, Yoshida A. Revisiting the guidelines issued by the Japanese Society of Thyroid Surgeons and Japan Association of Endocrine Surgeons: a gradual move towards consensus between Japanese and western practice in the management of thyroid carcinoma. World J Surg 2015; 38:2002-10. [PMID: 24671301 DOI: 10.1007/s00268-014-2498-y] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND In 2010, the Japanese Society of Thyroid Surgeons (JSTS) and Japanese Association of Endocrine Surgeons (JAES) established new guidelines entitled "Treatment of Thyroid Tumors." Since then, several new studies, including those that address the treatment of differentiated thyroid carcinoma (DTC) have been published, and the DTC treatment policy not only of Japanese physicians but those in Western countries has continued to evolve. METHODS We selected six clinical questions regarding the treatment of DTC and revisited them based on newly published data from Western countries and Japan. RESULTS More data have accumulated about treatment of low-risk papillary microcarcinoma. It has become clear that conservative treatment (observation) of low-risk papillary microcarcinoma in elderly patients is an acceptable alternative to immediate surgery. Total thyroidectomy versus hemithyroidectomy for low-risk papillary thyroid carcinoma (PTC) has become an important issue, and some publications after 2010 indicated that hemithyroidectomy is adequate for these low-risk patients. Unfortunately, no published manuscripts on prophylactic central node dissection offered good evidence regarding its indications or included a large number of patients. Also, it was not evident that prophylactic lateral node dissection improves cause-specific survival, although it might reduce lymph node recurrence especially in PTC patients with large tumors, distant metastases, or clinical central node metastases. Although completion total thyroidectomy was not recommended for minimally invasive follicular thyroid carcinoma in our guidelines, it may be better to perform it in elderly patients and those with a large tumor or extensive vascular invasion. Radioactive iodine (RAI) ablation after total thyroidectomy is still performed almost routinely in many Western institutions, although recent studies showed that ablation is not beneficial in low-risk patients. In Japan, because of legal restrictions, most patients did not undergo RAI ablation, and their prognoses are excellent. CONCLUSIONS Recently, policy for treating DTCs has changed not only in Western countries but also in Japan, resulting in a gradual move toward consensus between Western practice and ours. We will continue to present the best treatments for patients with thyroid carcinoma each time we revise our guidelines.
Collapse
|
34
|
Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, Tanaka K, Fukushima S, Takami H, Arita H, Kubo A, Shuto T, Ohno M, Miyakita Y, Kocialkowski S, Sasayama T, Hashimoto N, Maehara T, Shibui S, Ushijima T, Kawahara N, Narita Y, Ichimura K. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol 2015; 42:279-90. [PMID: 26111727 DOI: 10.1111/nan.12259] [Citation(s) in RCA: 145] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2015] [Accepted: 06/21/2015] [Indexed: 12/12/2022]
Abstract
AIMS Primary central nervous system lymphoma (PCNSL) manifest aggressive clinical behaviour and have poor prognosis. Although constitutive activation of the nuclear factor-κB (NF-κB) pathway has been documented, knowledge about the genetic alterations leading to the impairment of the NF-κB pathway in PCNSLs is still limited. This study was aimed to unravel the underlying genetic profiles of PCNSL. METHODS We conducted the systematic sequencing of 21 genes relevant to the NF-κB signalling network for 71 PCNSLs as well as the pyrosequencing of CD79B and MYD88 mutation hotspots in a further 35 PCNSLs and 46 glioblastomas (GBMs) for validation. RESULTS The results showed that 68 out of 71 PCNSLs had mutations in the NF-κB gene network, most commonly affecting CD79B (83%), MYD88 (76%), TBL1XR1 (23%), PRDM1 (20%) and CREBBP1 (20%). These mutations, particularly CD79B and MYD88, frequently coincided within each tumour in various combinations, simultaneously affecting diverse pathways within the network. No GBMs had hotspot mutation of CD79B Y196 and MYD88 L265. CONCLUSIONS The prevalence of CD79B and MYD88 mutations in PCNSLs was considerably higher than reported in systemic diffuse large B-cell lymphomas. This observation could reflect the paucity of antigen stimuli from the immune system in the central nervous system (CNS) and the necessity to substitute them by the constitutive activation of CD79B and MYD88 that would initiate the signalling cascades. These hotspot mutations may serve as a genetic hallmark for PCNSL serving as a genetic marker for diagnose and potential targets for molecular therapy.
Collapse
Affiliation(s)
- T Nakamura
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.,Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
| | - K Tateishi
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.,Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
| | - T Niwa
- Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan
| | - Y Matsushita
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - K Tamura
- Department of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan
| | - M Kinoshita
- Department of Neurosurgery, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - K Tanaka
- Department of Neurosurgery, Graduate School of Medicine, Kobe University, Kobe, Japan
| | - S Fukushima
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - H Takami
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| | - H Arita
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan.,Department of Neurosurgery, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - A Kubo
- Department of Neurosurgery, Yokosuka Kyosai Hospital, Yokosuka, Japan
| | - T Shuto
- Department of Neurosurgery, Yokohama Rosai Hospital, Yokohama, Japan
| | - M Ohno
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - Y Miyakita
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - S Kocialkowski
- Department of Pathology, University of Cambridge, Cambridge, UK
| | - T Sasayama
- Department of Neurosurgery, Graduate School of Medicine, Kobe University, Kobe, Japan
| | - N Hashimoto
- Department of Neurosurgery, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - T Maehara
- Department of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan
| | - S Shibui
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - T Ushijima
- Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan
| | - N Kawahara
- Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
| | - Y Narita
- Department of Neurosurgery and Neuro-oncology, National Cancer Center, Tokyo, Japan
| | - K Ichimura
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
| |
Collapse
|
35
|
Fukushima S, Yamashita S, Takami H, Fukuoka K, Narita Y, Ushijima T, Matsutani M, Nishikawa R, Ichimura K. GC-01 * ELUCIDATION OF PATHOGENESIS IN INTRACRANIAL GERM CELL TUMORS BASED ON A GENOME-WIDE METHYLATION STUDY. Neuro Oncol 2015. [DOI: 10.1093/neuonc/nov061.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Fukuoka K, Fukushima S, Yamashita S, Shofuda T, Nakamura T, Yamasaki K, Takami H, Matsushita Y, Ushijima T, Narita Y, Kanemura Y, Yamasaki M, Shibui S, Arai H, Nishikawa R, Ichimura K. EP-02 * MOLECULAR CLASSIFICATION OF EPENDYMOMAS IN A JAPANESE COHORT. Neuro Oncol 2015. [DOI: 10.1093/neuonc/nov061.21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Takami H, Burbelo PD, Fukuda K, Chang HS, Phillips SL, Yamada Y. Molecular organization and gene regulation of type IV collagen. Contrib Nephrol 2015; 107:36-46. [PMID: 8004973 DOI: 10.1159/000422959] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- H Takami
- Laboratory of Developmental Biology, National Institute of Dental Research, National Institutes of Health, Bethesda, Md
| | | | | | | | | | | |
Collapse
|
38
|
Sugimoto T, Matsumoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Fukunaga M, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Okubo N, Shiraki M, Nakamura T. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). Osteoporos Int 2015; 26:765-74. [PMID: 25403903 DOI: 10.1007/s00198-014-2964-2] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2014] [Accepted: 10/31/2014] [Indexed: 12/31/2022]
Abstract
SUMMARY A 12-month extension phase of DIRECT in Japanese subjects with osteoporosis showed that total 3 years of denosumab treatment in Japanese postmenopausal women and men with osteoporosis was associated with low fracture rates, persistent bone turnover marker (BTM) reductions, continuous bone mineral density (BMD) increases, and a favorable overall benefit/risk profile. INTRODUCTION The DIRECT trial demonstrated that 2 years of treatment with denosumab 60 mg subcutaneously every 6 months significantly reduced the incidence of vertebral fracture compared to placebo in Japanese postmenopausal women and men with osteoporosis. The purpose of this study is to evaluate the efficacy and safety of denosumab treatment for up to 3 years. METHODS This study includes a 2-year randomized, double-blind, placebo-controlled phase and a 1-year open-label extension phase in which all subjects received denosumab. The data correspond to 3 years of denosumab treatment in subjects who received denosumab (long-term group) and 1 year of denosumab treatment in subjects who received placebo (cross-over group) in the double-blind phase. RESULTS Eight hundred and ten subjects who completed the double-blind phase enrolled into the extension phase, and 775 subjects completed the study. All subjects received denosumab with daily supplements of calcium and vitamin D. The cumulative 36-month incidences of new or worsening vertebral fractures and new vertebral fractures were 3.8 and 2.5 %, respectively, in the long-term group. In this group, the BMD continued to increase, and the reduction in BTMs was maintained. In the cross-over group, comparable BMD increases and BTMs reductions to those of in their first year of the long-term group were confirmed. Adverse events did not show a notable increase with long-term denosumab administration. One event of osteonecrosis of the jaw occurred in the cross-over group. CONCLUSIONS Three-year denosumab treatment in Japanese subjects with osteoporosis showed a favorable benefit/risk profile.
Collapse
Affiliation(s)
- T Sugimoto
- Shimane University Faculty of Medicine, Izumo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Aleksić J, Ansoldi S, Antonelli LA, Antoranz P, Babic A, Bangale P, Barrio JA, González JB, Bednarek W, Bernardini E, Biasuzzi B, Biland A, Blanch O, Bonnefoy S, Bonnoli G, Borracci F, Bretz T, Carmona E, Carosi A, Colin P, Colombo E, Contreras JL, Cortina J, Covino S, Da Vela P, Dazzi F, De Angelis A, De Caneva G, De Lotto B, Wilhelmi EDO, Mendez CD, Prester DD, Dorner D, Doro M, Einecke S, Eisenacher D, Elsaesser D, Fonseca MV, Font L, Frantzen K, Fruck C, Galindo D, López RJG, Garczarczyk M, Terrats DG, Gaug M, Godinović N, Muñoz AG, Gozzini SR, Hadasch D, Hanabata Y, Hayashida M, Herrera J, Hildebrand D, Hose J, Hrupec D, Idec W, Kadenius V, Kellermann H, Kodani K, Konno Y, Krause J, Kubo H, Kushida J, La Barbera A, Lelas D, Lewandowska N, Lindfors E, Lombardi S, Longo F, López M, López-Coto R, López-Oramas A, Lorenz E, Lozano I, Makariev M, Mallot K, Maneva G, Mankuzhiyil N, Mannheim K, Maraschi L, Marcote B, Mariotti M, Martínez M, Mazin D, Menzel U, Miranda JM, Mirzoyan R, Moralejo A, Munar-Adrover P, Nakajima D, Niedzwiecki A, Nilsson K, Nishijima K, Noda K, Orito R, Overkemping A, Paiano S, Palatiello M, Paneque D, Paoletti R, Paredes JM, Paredes-Fortuny X, Persic M, Poutanen J, Moroni PGP, Prandini E, Puljak I, Reinthal R, Rhode W, Ribó M, Rico J, Garcia JR, Rügamer S, Saito T, Saito K, Satalecka K, Scalzotto V, Scapin V, Schultz C, Schweizer T, Shore SN, Sillanpää A, Sitarek J, Snidaric I, Sobczynska D, Spanier F, Stamatescu V, Stamerra A, Steinbring T, Storz J, Strzys M, Takalo L, Takami H, Tavecchio F, Temnikov P, Terzić T, Tescaro D, Teshima M, Thaele J, Tibolla O, Torres DF, Toyama T, Treves A, Uellenbeck M, Vogler P, Zanin R, Kadler M, Schulz R, Ros E, Bach U, Krauß F, Wilms J. Black hole lightning due to particle acceleration at subhorizon scales. Science 2014; 346:1080-4. [DOI: 10.1126/science.1256183] [Citation(s) in RCA: 100] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Affiliation(s)
- J. Aleksić
- Institut de Física d’Altes Energies, Campus UAB, E-08193 Bellaterra, Spain
| | - S. Ansoldi
- Università di Udine and Istituto Nazionale di Fisica Nucleare (INFN) Trieste, I-33100 Udine, Italy, and Istituto Nazionale di Astrofisica (INAF)-Trieste, I-34127 Trieste, Italy
| | - L. A. Antonelli
- INAF National Institute for Astrophysics, I-00136 Rome, Italy
| | - P. Antoranz
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - A. Babic
- Croatian MAGIC Consortium, Rudjer Boskovic Institute, University of Rijeka and University of Split, HR-10000 Zagreb, Croatia
| | - P. Bangale
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | | | - J. Becerra González
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, Tenerife, Spain
- Present address: NASA Goddard Space Flight Center, Greenbelt, MD 20771, USA, and Department of Physics and Department of Astronomy, University of Maryland, College Park, MD 20742, USA
| | | | - E. Bernardini
- Deutsches Elektronen-Synchrotron, D-15738 Zeuthen, Germany
| | - B. Biasuzzi
- Università di Udine and Istituto Nazionale di Fisica Nucleare (INFN) Trieste, I-33100 Udine, Italy, and Istituto Nazionale di Astrofisica (INAF)-Trieste, I-34127 Trieste, Italy
| | - A. Biland
- ETH Zurich, CH-8093 Zurich, Switzerland
| | - O. Blanch
- Institut de Física d’Altes Energies, Campus UAB, E-08193 Bellaterra, Spain
| | - S. Bonnefoy
- Universidad Complutense, E-28040 Madrid, Spain
| | - G. Bonnoli
- INAF National Institute for Astrophysics, I-00136 Rome, Italy
| | - F. Borracci
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - T. Bretz
- Universität Würzburg, D-97074 Würzburg, Germany
- Present address: Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - E. Carmona
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, E-28040 Madrid, Spain
| | - A. Carosi
- INAF National Institute for Astrophysics, I-00136 Rome, Italy
| | - P. Colin
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - E. Colombo
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, Tenerife, Spain
| | | | - J. Cortina
- Institut de Física d’Altes Energies, Campus UAB, E-08193 Bellaterra, Spain
| | - S. Covino
- INAF National Institute for Astrophysics, I-00136 Rome, Italy
| | - P. Da Vela
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - F. Dazzi
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - A. De Angelis
- Università di Udine and Istituto Nazionale di Fisica Nucleare (INFN) Trieste, I-33100 Udine, Italy, and Istituto Nazionale di Astrofisica (INAF)-Trieste, I-34127 Trieste, Italy
| | - G. De Caneva
- Deutsches Elektronen-Synchrotron, D-15738 Zeuthen, Germany
| | - B. De Lotto
- Università di Udine and Istituto Nazionale di Fisica Nucleare (INFN) Trieste, I-33100 Udine, Italy, and Istituto Nazionale di Astrofisica (INAF)-Trieste, I-34127 Trieste, Italy
| | | | - C. Delgado Mendez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, E-28040 Madrid, Spain
| | - D. Dominis Prester
- Croatian MAGIC Consortium, Rudjer Boskovic Institute, University of Rijeka and University of Split, HR-10000 Zagreb, Croatia
| | - D. Dorner
- Universität Würzburg, D-97074 Würzburg, Germany
| | - M. Doro
- Università di Padova and INFN, I-35131 Padova, Italy
| | - S. Einecke
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | | | | | | | - L. Font
- Unitat de Física de les Radiacions, Departament de Física, and Centro de Estudios e Investigación Espaciales-Institut d’Estudis Espacials de Catalunya, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain
| | - K. Frantzen
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - C. Fruck
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - D. Galindo
- Universitat de Barcelona, Institut de Ciències del Cosmos, Institut d’Estudis Espacials de Catalunya-Universitat de Barcelona, E-08028 Barcelona, Spain
| | - R. J. García López
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, Tenerife, Spain
| | - M. Garczarczyk
- Deutsches Elektronen-Synchrotron, D-15738 Zeuthen, Germany
| | - D. Garrido Terrats
- Unitat de Física de les Radiacions, Departament de Física, and Centro de Estudios e Investigación Espaciales-Institut d’Estudis Espacials de Catalunya, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain
| | - M. Gaug
- Unitat de Física de les Radiacions, Departament de Física, and Centro de Estudios e Investigación Espaciales-Institut d’Estudis Espacials de Catalunya, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain
| | - N. Godinović
- Croatian MAGIC Consortium, Rudjer Boskovic Institute, University of Rijeka and University of Split, HR-10000 Zagreb, Croatia
| | - A. González Muñoz
- Institut de Física d’Altes Energies, Campus UAB, E-08193 Bellaterra, Spain
| | - S. R. Gozzini
- Deutsches Elektronen-Synchrotron, D-15738 Zeuthen, Germany
| | - D. Hadasch
- Institute of Space Sciences, E-08193 Barcelona, Spain
- Present address: Institut für Astro- und Teilchenphysik, Leopold-Franzens-Universität Innsbruck, A-6020 Innsbruck, Austria
| | - Y. Hanabata
- Japanese MAGIC Consortium, Division of Physics and Astronomy, Kyoto University, Japan
| | - M. Hayashida
- Japanese MAGIC Consortium, Division of Physics and Astronomy, Kyoto University, Japan
| | - J. Herrera
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, Tenerife, Spain
| | | | - J. Hose
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - D. Hrupec
- Croatian MAGIC Consortium, Rudjer Boskovic Institute, University of Rijeka and University of Split, HR-10000 Zagreb, Croatia
| | - W. Idec
- University of Łódz', PL-90236 Lodz, Poland
| | - V. Kadenius
- Finnish MAGIC Consortium, Tuorla Observatory, University of Turku and Department of Physics, University of Oulu, Finland
| | - H. Kellermann
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - K. Kodani
- Japanese MAGIC Consortium, Division of Physics and Astronomy, Kyoto University, Japan
| | - Y. Konno
- Japanese MAGIC Consortium, Division of Physics and Astronomy, Kyoto University, Japan
| | - J. Krause
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - H. Kubo
- Japanese MAGIC Consortium, Division of Physics and Astronomy, Kyoto University, Japan
| | - J. Kushida
- Japanese MAGIC Consortium, Division of Physics and Astronomy, Kyoto University, Japan
| | - A. La Barbera
- INAF National Institute for Astrophysics, I-00136 Rome, Italy
| | - D. Lelas
- Croatian MAGIC Consortium, Rudjer Boskovic Institute, University of Rijeka and University of Split, HR-10000 Zagreb, Croatia
| | | | - E. Lindfors
- Finnish MAGIC Consortium, Tuorla Observatory, University of Turku and Department of Physics, University of Oulu, Finland
- Present address: Finnish Centre for Astronomy with ESO (FINCA), Turku, Finland
| | - S. Lombardi
- INAF National Institute for Astrophysics, I-00136 Rome, Italy
| | - F. Longo
- Università di Udine and Istituto Nazionale di Fisica Nucleare (INFN) Trieste, I-33100 Udine, Italy, and Istituto Nazionale di Astrofisica (INAF)-Trieste, I-34127 Trieste, Italy
| | - M. López
- Universidad Complutense, E-28040 Madrid, Spain
| | - R. López-Coto
- Institut de Física d’Altes Energies, Campus UAB, E-08193 Bellaterra, Spain
| | - A. López-Oramas
- Institut de Física d’Altes Energies, Campus UAB, E-08193 Bellaterra, Spain
| | | | - I. Lozano
- Universidad Complutense, E-28040 Madrid, Spain
| | - M. Makariev
- Institute for Nuclear Research and Nuclear Energy, BG-1784 Sofia, Bulgaria
| | - K. Mallot
- Deutsches Elektronen-Synchrotron, D-15738 Zeuthen, Germany
| | - G. Maneva
- Institute for Nuclear Research and Nuclear Energy, BG-1784 Sofia, Bulgaria
| | - N. Mankuzhiyil
- Università di Udine and Istituto Nazionale di Fisica Nucleare (INFN) Trieste, I-33100 Udine, Italy, and Istituto Nazionale di Astrofisica (INAF)-Trieste, I-34127 Trieste, Italy
- Present address: Astrophysics Science Division, Bhabha Atomic Research Centre, Mumbai 400085, India
| | - K. Mannheim
- Universität Würzburg, D-97074 Würzburg, Germany
| | - L. Maraschi
- INAF National Institute for Astrophysics, I-00136 Rome, Italy
| | - B. Marcote
- Universitat de Barcelona, Institut de Ciències del Cosmos, Institut d’Estudis Espacials de Catalunya-Universitat de Barcelona, E-08028 Barcelona, Spain
| | - M. Mariotti
- Università di Padova and INFN, I-35131 Padova, Italy
| | - M. Martínez
- Institut de Física d’Altes Energies, Campus UAB, E-08193 Bellaterra, Spain
| | - D. Mazin
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - U. Menzel
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - J. M. Miranda
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - R. Mirzoyan
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - A. Moralejo
- Institut de Física d’Altes Energies, Campus UAB, E-08193 Bellaterra, Spain
| | - P. Munar-Adrover
- Universitat de Barcelona, Institut de Ciències del Cosmos, Institut d’Estudis Espacials de Catalunya-Universitat de Barcelona, E-08028 Barcelona, Spain
| | - D. Nakajima
- Japanese MAGIC Consortium, Division of Physics and Astronomy, Kyoto University, Japan
| | | | - K. Nilsson
- Finnish MAGIC Consortium, Tuorla Observatory, University of Turku and Department of Physics, University of Oulu, Finland
- Present address: Finnish Centre for Astronomy with ESO (FINCA), Turku, Finland
| | - K. Nishijima
- Japanese MAGIC Consortium, Division of Physics and Astronomy, Kyoto University, Japan
| | - K. Noda
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - R. Orito
- Japanese MAGIC Consortium, Division of Physics and Astronomy, Kyoto University, Japan
| | - A. Overkemping
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - S. Paiano
- Università di Padova and INFN, I-35131 Padova, Italy
| | - M. Palatiello
- Università di Udine and Istituto Nazionale di Fisica Nucleare (INFN) Trieste, I-33100 Udine, Italy, and Istituto Nazionale di Astrofisica (INAF)-Trieste, I-34127 Trieste, Italy
| | - D. Paneque
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - R. Paoletti
- Università di Siena and INFN Pisa, I-53100 Siena, Italy
| | - J. M. Paredes
- Universitat de Barcelona, Institut de Ciències del Cosmos, Institut d’Estudis Espacials de Catalunya-Universitat de Barcelona, E-08028 Barcelona, Spain
| | - X. Paredes-Fortuny
- Universitat de Barcelona, Institut de Ciències del Cosmos, Institut d’Estudis Espacials de Catalunya-Universitat de Barcelona, E-08028 Barcelona, Spain
| | - M. Persic
- Università di Udine and Istituto Nazionale di Fisica Nucleare (INFN) Trieste, I-33100 Udine, Italy, and Istituto Nazionale di Astrofisica (INAF)-Trieste, I-34127 Trieste, Italy
| | - J. Poutanen
- Finnish MAGIC Consortium, Tuorla Observatory, University of Turku and Department of Physics, University of Oulu, Finland
| | | | | | - I. Puljak
- Croatian MAGIC Consortium, Rudjer Boskovic Institute, University of Rijeka and University of Split, HR-10000 Zagreb, Croatia
| | - R. Reinthal
- Finnish MAGIC Consortium, Tuorla Observatory, University of Turku and Department of Physics, University of Oulu, Finland
| | - W. Rhode
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - M. Ribó
- Universitat de Barcelona, Institut de Ciències del Cosmos, Institut d’Estudis Espacials de Catalunya-Universitat de Barcelona, E-08028 Barcelona, Spain
| | - J. Rico
- Institut de Física d’Altes Energies, Campus UAB, E-08193 Bellaterra, Spain
| | | | - S. Rügamer
- Universität Würzburg, D-97074 Würzburg, Germany
| | - T. Saito
- Japanese MAGIC Consortium, Division of Physics and Astronomy, Kyoto University, Japan
| | - K. Saito
- Japanese MAGIC Consortium, Division of Physics and Astronomy, Kyoto University, Japan
| | | | - V. Scalzotto
- Università di Padova and INFN, I-35131 Padova, Italy
| | - V. Scapin
- Universidad Complutense, E-28040 Madrid, Spain
| | - C. Schultz
- Università di Padova and INFN, I-35131 Padova, Italy
| | - T. Schweizer
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - S. N. Shore
- Università di Pisa and INFN Pisa, I-56126 Pisa, Italy
| | - A. Sillanpää
- Finnish MAGIC Consortium, Tuorla Observatory, University of Turku and Department of Physics, University of Oulu, Finland
| | - J. Sitarek
- Institut de Física d’Altes Energies, Campus UAB, E-08193 Bellaterra, Spain
| | - I. Snidaric
- Croatian MAGIC Consortium, Rudjer Boskovic Institute, University of Rijeka and University of Split, HR-10000 Zagreb, Croatia
| | | | - F. Spanier
- Universität Würzburg, D-97074 Würzburg, Germany
| | - V. Stamatescu
- Institut de Física d’Altes Energies, Campus UAB, E-08193 Bellaterra, Spain
- Present address: School of Chemistry and Physics, University of Adelaide, Adelaide 5005, Australia
| | - A. Stamerra
- INAF National Institute for Astrophysics, I-00136 Rome, Italy
| | | | - J. Storz
- Universität Würzburg, D-97074 Würzburg, Germany
| | - M. Strzys
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - L. Takalo
- Finnish MAGIC Consortium, Tuorla Observatory, University of Turku and Department of Physics, University of Oulu, Finland
| | - H. Takami
- Japanese MAGIC Consortium, Division of Physics and Astronomy, Kyoto University, Japan
| | - F. Tavecchio
- INAF National Institute for Astrophysics, I-00136 Rome, Italy
| | - P. Temnikov
- Institute for Nuclear Research and Nuclear Energy, BG-1784 Sofia, Bulgaria
| | - T. Terzić
- Croatian MAGIC Consortium, Rudjer Boskovic Institute, University of Rijeka and University of Split, HR-10000 Zagreb, Croatia
| | - D. Tescaro
- Instituto de Astrofísica de Canarias, E-38200 La Laguna, Tenerife, Spain
| | - M. Teshima
- Max-Planck-Institut für Physik, D-80805 München, Germany
- Japanese MAGIC Consortium, Division of Physics and Astronomy, Kyoto University, Japan
| | - J. Thaele
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - O. Tibolla
- Universität Würzburg, D-97074 Würzburg, Germany
| | - D. F. Torres
- ICREA and Institute of Space Sciences, E-08193 Barcelona, Spain
| | - T. Toyama
- Max-Planck-Institut für Physik, D-80805 München, Germany
| | - A. Treves
- Università dell’Insubria and INFN Milano Bicocca, Como, I-22100 Como, Italy
| | - M. Uellenbeck
- Technische Universität Dortmund, D-44221 Dortmund, Germany
| | - P. Vogler
- ETH Zurich, CH-8093 Zurich, Switzerland
| | - R. Zanin
- Universitat de Barcelona, Institut de Ciències del Cosmos, Institut d’Estudis Espacials de Catalunya-Universitat de Barcelona, E-08028 Barcelona, Spain
| | - M. Kadler
- Universität Würzburg, D-97074 Würzburg, Germany
| | - R. Schulz
- Universität Würzburg, D-97074 Würzburg, Germany
- Dr. Remeis-Sternwarte Bamberg, Astronomisches Institut der Universität Erlangen-Nürnberg, ECAP, D-96049 Bamberg, Germany
| | - E. Ros
- Max-Planck-Institut für Radioastronomie, D-53121 Bonn, Germany
- Observatori Astronòmic, Universitat de València, E-46980 Paterna, València, Spain
- Departament d’Astronomia i Astrofísica, Universitat de València, E-46100 Burjassot, València, Spain
| | - U. Bach
- Max-Planck-Institut für Radioastronomie, D-53121 Bonn, Germany
| | - F. Krauß
- Universität Würzburg, D-97074 Würzburg, Germany
- Dr. Remeis-Sternwarte Bamberg, Astronomisches Institut der Universität Erlangen-Nürnberg, ECAP, D-96049 Bamberg, Germany
| | - J. Wilms
- Dr. Remeis-Sternwarte Bamberg, Astronomisches Institut der Universität Erlangen-Nürnberg, ECAP, D-96049 Bamberg, Germany
| |
Collapse
|
40
|
Brandt TD, McElwain MW, Turner EL, Mede K, Spiegel DS, Kuzuhara M, Schlieder JE, Wisniewski JP, Abe L, Biller B, Brandner W, Carson J, Currie T, Egner S, Feldt M, Golota T, Goto M, Grady CA, Guyon O, Hashimoto J, Hayano Y, Hayashi M, Hayashi S, Henning T, Hodapp KW, Inutsuka S, Ishii M, Iye M, Janson M, Kandori R, Knapp GR, Kudo T, Kusakabe N, Kwon J, Matsuo T, Miyama S, Morino JI, Moro-Martín A, Nishimura T, Pyo TS, Serabyn E, Suto H, Suzuki R, Takami M, Takato N, Terada H, Thalmann C, Tomono D, Watanabe M, Yamada T, Takami H, Usuda T, Tamura M. A STATISTICAL ANALYSIS OF SEEDS AND OTHER HIGH-CONTRAST EXOPLANET SURVEYS: MASSIVE PLANETS OR LOW-MASS BROWN DWARFS? ACTA ACUST UNITED AC 2014. [DOI: 10.1088/0004-637x/794/2/159] [Citation(s) in RCA: 118] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
41
|
Kanda M, Shimizu D, Sugimoto H, Oya H, Hibino S, Takami H, Hashimoto R, Okamura Y, Yamada S, Fujii T, Nakayama G, Koike M, Nomoto S, Fujiwara M, Kodera Y. B-Cell Translocation Gene 1 Serves As a Novel Prognostic Indicator of Hepatocellular Carcinoma. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Shimizu D, Kanda M, Sugimoto H, Oya H, Takami H, Hibino S, Hashimoto R, Okamura Y, Yamada S, Fujii T, Nakayama G, Koike M, Nomoto S, Fujiwara M, Kodera Y. Identification of Intragenic Methylation in the Tusc1 Gene As a Novel Prognostic Marker of Hepatocellular Carcinoma. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Matsutani M, Takami H, Fukuoka K, Mishima K, Nishikawa R, Icimura K. POTENCY OF SECRETING HCG- IN GERMINOMAS. CLINICAL AND BIOLOGICAL ANALYSIS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou208.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Ichimura K, Fukushima S, Totoki Y, Matsushita Y, Otsuka A, Tomiyama A, Niwa T, Sakai R, Ushijima T, Nakamura T, Suzuki T, Fukuoka K, Yanagisawa T, Mishima K, Nakazato Y, Hosoda F, Narita Y, Shibui S, Yoshida A, Takami H, Mukasa A, Aihara K, Saito N, Kumabe T, Kanamori M, Tominaga T, Kobayashi K, Shimizu S, Nagane M, Iuchi T, Mizoguchi M, Yoshimoto K, Tamura K, Maehara T, Sugiyama K, Nakada M, Sakai K, Kanemura Y, Yokogami K, Takeshima H, Kawahara N, Takayama T, Yao M, Matsutani M, Shibata T, Nishikawa R. WHOLE EXOME SEQUENCING IDENTIFIED THAT THE MAPK AND PI3K PATHWAYS ARE THE MAIN TARGETS FOR MUTATIONS IN INTRACRANIAL GERM CELL TUMORS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou208.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Affiliation(s)
- H Takami
- Microbiology Laboratory, Institute of Physical and Chemical Research, Saitama, Japan
| | | | | |
Collapse
|
46
|
Takami H, Kobayashi T, Kobayashi M, Yamamoto M, Nakamura S, Aono R, Horikoshi K. Molecular Cloning, Nucleotide Sequence, and Expression of the Structural Gene for Alkaline Serine Protease from AlkaliphilicBacillussp. 221. Biosci Biotechnol Biochem 2014; 56:1455-60. [PMID: 1368952 DOI: 10.1271/bbb.56.1455] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The gene encoding an alkaline serine protease from alkaliphilic Bacillus sp. 221 was cloned in Escherichia coli and expressed in Bacillus subtilis. An open reading frame of 1,140 bases, identified as the protease gene was preceded by a putative Shine-Dalgarno sequence (AGGAGG) with a spacing of 7 bases. The deduced amino acid sequence had a pre-pro-peptide of 111 residues followed by the mature protease comprising 269 residues. The alkaline protease from alkaliphilic Bacillus sp. 221 had higher homology to the protease from alkaliphilic bacilli (82.1% and 99.6%) than to those from neutrophilic bacilli (60.6-61.7%). Also Bacillus sp. 221 protease and other protease from alkaliphilic bacilli shared common amino acid changes and 4 amino acid deletions that seemed to be related to characteristics of the enzyme of alkaliphilic bacilli when compared to the proteases from neutrophilic bacilli.
Collapse
Affiliation(s)
- H Takami
- Department of Bioengineering, Tokyo Institute of Technology, Kanagawa, Japan
| | | | | | | | | | | | | |
Collapse
|
47
|
Kannan V, Misra BK, Kapadia A, Bajpai R, Deshpande S, Almel S, Sankhe M, Desai K, Shaikh M, Anand V, Kannan A, Teo WY, Ross J, Bollo R, Seow WT, Tan AM, Kang SG, Kim DS, Li XN, Lau CC, Mohila CA, Adesina A, Su J, Ichimura K, Fukushima S, Matsushita Y, Tomiyama A, Niwa T, Suzuki T, Nakazato Y, Mukasa A, Kumabe T, Nagane M, Iuchi T, Mizoguchi M, Tamura K, Sugiyama K, Nakada M, Kanemura Y, Yokogami K, Matsutani M, Shibata T, Nishikawa R, Takami H, Fukushima S, Fukuoka K, Yanagisawa T, Nakamura T, Arita H, Narita Y, Shibui S, Nishikawa R, Ichimura K, Matsutani M, Sands S, Guerry W, Kretschmar C, Donahue B, Allen J, Matsutani M, Nishikawa R, Kumabe T, Sugiyama K, Nakamura H, Sawamura Y, Fujimaki T, Hattori E, Arakawa Y, Kawabata Y, Aoki T, Miyamoto S, Kagawa N, Hirayama R, Fujimoto Y, Chiba Y, Kinoshita M, Takano K, Eino D, Fukuya S, Nakanishi K, Yamamoto F, Hashii Y, Hashimoto N, Hara J, Yoshimine T, Murray M, Bartels U, Nishikawa R, Fangusaro J, Matsutani M, Nicholson J, Sumerauer D, Zapotocky M, Churackova M, Cyprova S, Zamecnik J, Malinova B, Kyncl M, Tichy M, Stary J, Lassen-Ramshad Y, von Oettingen G, Agerbaek M, Ohnishi T, Kohno S, Inoue A, Ohue S, Kohno S, Iwata S, Inoue A, Ohue S, Kumon Y, Ohnishi T, Acharya S, DeWees T, Shinohara E, Perkins S, Kato H, Fuji H, Nakasu Y, Ishida Y, Okawada S, Yang Q, Guo C, Chen Z, Alapetite C, Faure-Conter C, Verite C, Pagnier A, Laithier V, Entz-Werle N, Gorde-Grosjean S, Palenzuela G, Lemoine P, Frappaz D, Nguyen HA, Bui L, Ngoc, Cerbone M, Ederies A, Losa L, Moreno C, Sun K, Spoudeas HA, Nakano Y, Okada K, Kosaka Y, Nagashima T, Hashii Y, Kagawa N, Soejima T, Osugi Y, Sakamoto H, Hara J, Nicholson J, Alapetite C, Kortmann RD, Garre ML, Ricardi U, Saran F, Frappaz D, Calaminus G, Muda Z, Menon B, Ibrahim H, Rahman EJA, Muhamad M, Othman IS, Thevarajah A, Cheng S, Kilday JP, Laperriere N, Drake J, Bouffet E, Bartels U, Sakamoto H, Matsusaka Y, Watanabe Y, Umaba R, Hara J, Osugi Y, Alapetite C, Ruffier-Loubiere A, De Marzi L, Bolle S, Claude L, Habrand JL, Brisse H, Frappaz D, Doz F, Bourdeaut F, Dendale R, Mazal A, Fournier-Bidoz N, Fujimaki T, Fukuoka K, Shirahata M, Suzuki T, Adachi JI, Mishima K, Wakiya K, Matsutani M, Nishikawa R, Fukushima S, Yamashita S, Kato M, Nakamura H, Takami H, Suzuki T, Yanagisawa T, Mukasa A, Kumabe T, Nagane M, Sugiyama K, Tamura K, Narita Y, Shibui S, Shibata T, Ushijima T, Matsutani M, Nishikawa R, Ichimura K, Consortium IGA, Calaminus G, Kortmann RD, Frappaz D, Alapetite C, Garre ML, Ricardi U, Saran FH, Nicholson J, Calaminus G, Kortmann RD, Frappaz D, Alapetite C, Garre ML, Ricardi U, Saran FH, Nicholson J, Czech T, Nicholson J, Frappaz D, Kortmann RD, Alapetite C, Garre ML, Ricardi U, Saran F, Calaminus G, Hayden J, Bartels U, Calaminus G, Joseph R, Nicholson J, Hale J, Lindsay H, Kogiso M, Qi L, Yee TW, Huang Y, Mao H, Lin F, Baxter P, Su J, Terashima K, Perlaky L, Lau C, Parsons D, Chintagumpala M, Li XAN, Osorio D, Vaughn D, Gardner S, Mrugala M, Ferreira M, Keene C, Gonzalez-Cuyar L, Hebb A, Rockhill J, Wang L, Yamaguchi S, Burstein M, Terashima K, Ng HK, Nakamura H, He Z, Suzuki T, Nishikawa R, Natsume A, Terasaka S, Dauser R, Whitehead W, Adesina A, Sun J, Munzy D, Gibbs R, Leal S, Wheeler D, Lau C, Dhall G, Robison N, Judkins A, Krieger M, Gilles F, Park J, Lee SU, Kim T, Choi Y, Park HJ, Shin SH, Kim JY, Robison N, Dhir N, Khamani J, Margol A, Wong K, Britt B, Evans A, Nelson M, Grimm J, Finlay J, Dhall G. GERM CELL TUMOURS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Kodama K, Takami H, Izumi M, Hiramoto Y, Yoshida K, Nishioka K, Higashiyama M. Late cardiac effect of radiation therapy on a young woman with mediastinal Hodgkin's lymphoma. Gen Thorac Cardiovasc Surg 2014; 64:51-4. [PMID: 24852447 DOI: 10.1007/s11748-014-0423-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2014] [Accepted: 05/04/2014] [Indexed: 02/01/2023]
Abstract
We experienced an excision of the mediastinal tumor located in left anterior mediastinum found in a 21-year-old woman. The histologic diagnosis of Hodgkin's lymphoma was obtained. After operation, she was treated with mantle field radiotherapy (total 42 Gy) followed by chemotherapy. At 43-year old, she developed constrictive pericarditis and heart failure resulted in the late cardiac effects of mediastinal irradiation. Despite pericardiectomy followed by medical treatment, her cardiac symptoms gradually worsened and she died at 51-year old. At autopsy, her heart was smaller than normal person. The residual pericardium and the surface of the myocardium had fibrous degeneration with tight adhesion and thickness that were dominant at the right atrium and ventricle. Likewise, we demonstrated that pericardiectomy scarcely led to a favorable outcome in this patient. These facts might be based on the radiation-associated cardiac effects involving any components of the cardiac structure.
Collapse
Affiliation(s)
- Ken Kodama
- Department of Thoracic Surgery, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka, 581-0069, Japan.
| | - Hiroshi Takami
- Department of Cardiology, Kinki Central Hospital, Itami, Hyogo, Japan
| | - Masahiro Izumi
- Department of Cardiology, Kinki Central Hospital, Itami, Hyogo, Japan
| | | | - Kyotaro Yoshida
- Department of Pathology, Kinki Central Hospital, Itami, Hyogo, Japan
| | | | - Masahiko Higashiyama
- Department of Thoracic Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
| |
Collapse
|
49
|
Fujii T, Kanda M, Suenaga M, Takami H, Inokawa Y, Yamada S, Sugimoto H, Nomoto S, Kodera Y. Preoperative Internal Biliary Drainage Increases the Risk of Bile Juice Infection and Pancreatic Fistula after Pancreatoduodenectomy: A Prospective Observational Study. J Surg Res 2014. [DOI: 10.1016/j.jss.2013.11.588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
50
|
Oshima Y, Niki K, Hiramoto Y, Morimoto S, Takami H, Izumi M. Serum eicosapentaenoic acid/arachidonic acid ratio is low in patients with pulmonary thromboembolism. J Nutr Sci Vitaminol (Tokyo) 2014; 59:474-7. [PMID: 24418883 DOI: 10.3177/jnsv.59.474] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Recently n-3 polyunsaturated fatty acids (PUFAs) have been reported to play protective roles against cardiovascular diseases. Pulmonary thromboembolism (PTE) is one of the critical diseases in the circulatory system. However the relationship between n-3 PUFAs and PTE has not been reported. A total of 144 outpatients of the division of cardiology, including 12 of PTE cases, were enrolled in the present study and serum levels of eicosapentaenoic acid (EPA) and arachidonic acid (AA) were analyzed. We found that the EPA/AA ratio of the patients with PTE (the PTE group) was significantly lower than that of the patients without PTE (the non-PTE group) (p=0.007 for log EPA/log AA ratio). Next, the PTE group was divided into two groups by the presence or absence of malignant carcinoma. The PTE without carcinoma group showed significantly lower EPA/AA ratio than that of the non-PTE group (p=0.002 for log EPA/log AA ratio). However, the PTE with carcinoma group did not show the statistical difference in EPA/AA ratio compared with the non-PTE group (p=0.39). These data indicate that PTE may be associated with a low EPA/AA ratio, although the presence of malignant carcinoma should be taken into account.
Collapse
Affiliation(s)
- Yuichi Oshima
- Division of Cardiology, Department of Internal Medicine, Kinki Central Hospital
| | | | | | | | | | | |
Collapse
|